

Rhee Yumie (Orcid ID: 0000-0003-4227-5638)
 Imanishi Yasuo (Orcid ID: 0000-0002-9077-2631)
 Xia Weibo (Orcid ID: 0000-0001-7768-5536)

Asia-Pacific Consensus Recommendations on X-Linked Hypophosphatemia: Diagnosis, Multidisciplinary Management, and Transition from Pediatric to Adult Care

Authors

Munns CF¹, Yoo HW², Jalaludin MY³, Vasanwala RF⁴, Chandran M⁵, Rhee Y⁶, But WM⁷, Kong AP⁸, Su PH⁹, Numbenjapon N¹⁰, Namba N¹¹, Imanishi Y¹², Clifton-Bligh R¹³, Luo X¹⁴, Xia W¹⁵

Author affiliations

¹Child Health Research Centre, The University of Queensland, Brisbane, Australia; Department of Endocrinology and Diabetes, Queensland Children's Hospital, Brisbane, QLD, Australia

²Department of Pediatrics, Bundang CHA Medical Center, CHA University School of Medicine, Korea

³Department of Pediatrics, Faculty of Medicine, Universiti Malaya, Malaysia

⁴Department of Paediatric Medicine, Endocrine & Diabetes Service, KK Women's & Children's Hospital, Singapore

⁵Osteoporosis and bone metabolism unit, Department of Endocrinology, Singapore General Hospital, Singapore

⁶Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea

⁷Department of Pediatrics, Queen Elizabeth Hospital, Hong Kong

⁸Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong

⁹Department of Pediatrics, Chung Shan Medical University hospital, Taichung, Taiwan; School of Medicine, Chung Shan Medical University, Taichung, Taiwan

¹⁰Division of Endocrinology, Department of Pediatrics, Phramongkutklo Hospital, Thailand

¹¹Department of Pediatrics and Perinatology, Faculty of Medicine, Tottori University, Japan

¹²Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Japan

¹³Department of Endocrinology, Royal North Shore Hospital, University of Sydney, Australia

¹⁴Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China

¹⁵Department of Endocrinology, Key Laboratory of Endocrinology, NHC, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Corresponding authors

Craig F Munns

Child Health Research Centre,
 The University of Queensland,
 South Brisbane, Queensland, Australia
 E: c.munns@uq.edu.au

Weibo Xia

Department of Endocrinology,

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the [Version of Record](#). Please cite this article as doi: [10.1002/jbm4.10744](https://doi.org/10.1002/jbm4.10744)

Key Laboratory of Endocrinology, NHC, State Key Laboratory of Complex Severe and Rare Diseases,
Peking Union Medical College Hospital,
Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
E: xiaweibo8301@163.com

Abstract

X-linked hypophosphatemia (XLH) is a rare, inherited, multisystem disorder characterized by hypophosphatemia that occurs secondary to renal phosphate wasting. Mutations in PHEX gene (located at Xp22.1) in XLH alter bone mineral metabolism, resulting in diverse skeletal, dental and other extra-skeletal abnormalities that become evident in early childhood and persist into adolescence and adult life. XLH impacts physical function, mobility, and quality of life, and is associated with substantial socioeconomic burden and healthcare resource utilization. As the burden of illness varies with age, an appropriate transition of care from childhood and adolescence to adulthood is necessary to meet growth-related changes and minimize long-term sequelae of the condition. Previous XLH guidelines that encompassed transition of care have focused on Western experience. Regional differences in resource availability warrant tailoring of recommendations to the Asia-Pacific (APAC) context. Hence, a core expert panel of 15 pediatric and adult endocrinologists from 9 countries/regions across APAC convened to formulate evidence-based recommendations for optimizing XLH care. A comprehensive literature search on PubMed using MeSH and free-text terms relevant to pre-determined clinical questions on diagnosis, multidisciplinary management, and transition of care of XLH, revealed 2171 abstracts. The abstracts were reviewed independently by 2 authors to shortlist a final of 164 articles. A total of 92 full text articles were finally selected for data extraction and drafting the consensus statements. Sixteen guiding statements were developed based on review of evidence and real-world clinical experience. The GRADE criteria were used to appraise the quality of evidence supporting the statements. Subsequently, a Delphi technique was utilized to rate the agreement on statements; 38 XLH experts (15 core, 20 additional, 3 international) from 15 countries/regions (12 APAC, 3 EU) participated in the Delphi voting to further refine the statements. Statements 1–3 cover the screening and diagnosis of pediatric and adult XLH; we have defined the clinical, imaging, biochemical, and genetic criteria and raised red flags for the presumptive and confirmatory diagnosis of XLH. Statements 4–12 tackle elements of multidisciplinary management in XLH such as therapeutic goals and options, composition of the multidisciplinary team, follow-up assessments, required monitoring schedules and the role of telemedicine. Treatment with active vitamin D, oral phosphate, and burosumab is discussed in terms of applicability to APAC settings. We also expound on multidisciplinary care for different age groups (children, adolescents, adults) and pregnant or lactating women. Statements 13–15 address facets of the transition from pediatric to adult care: targets and timelines, roles and responsibilities of stakeholders and process flow. We explain the use of validated questionnaires, desirable characteristics of a transition care clinic, and important components of a transfer letter. Lastly, strategies to improve XLH education to the medical community are also elaborated in statement 16. Overall, optimized care for XLH patients requires prompt diagnosis, timely multidisciplinary care, and a seamless transfer of care through the coordinated effort of pediatric and adult healthcare providers, nurse practitioners, parents or caregivers, and patients. To achieve this end, we provide specific guidance for clinical practice in APAC settings.

Keywords: X-linked hypophosphatemic rickets; care transition; practice guidelines; Asia; Asia-Pacific

1. Introduction

X-linked hypophosphatemia (XLH) is a rare, genetic, multisystem disorder characterized by renal phosphate wasting. Mutations in the Phosphate Endopeptidase Homolog, X-linked (PHEX) gene (located at Xp22.1) that encodes a transmembrane endopeptidase, primarily expressed in osteoblasts, osteocytes and teeth, cause elevated fibroblast growth factor 23 (FGF23) and consequent renal phosphate wasting and defects in the hydroxylation of vitamin D. The altered mineral metabolism then leads to diverse skeletal abnormalities, including rickets, osteomalacia, and dental health issues.⁽¹⁻⁷⁾

XLH is the most frequent cause of inherited hypophosphatemia and the most common genetic etiology of rickets with a prevalence of ~15–48 per 1 million individuals.⁽⁸⁻¹⁰⁾ In terms of the Asia-Pacific (APAC) region, an incidence of 1 in 20,000 was reported in Japan.⁽¹¹⁾ The symptoms and complications of XLH begin in early childhood, potentially leading to short stature and limb deformities. They may also extend into or develop further during adulthood, causing continued impairment of function, mobility, and quality of life (QoL), as well as increased health care resource utilization.⁽¹²⁻¹⁴⁾ In fact, adults with XLH may even have reduced survival compared with healthy controls.⁽⁸⁾

Burden-of-disease surveys in various parts of the world, including East Asia, reveal that despite conventional pharmacologic treatment with oral phosphate and active vitamin D, XLH imposes a lifelong disability from childhood to adulthood.^(15,16) The higher prevalence of comorbidities in XLH patients, such as depression, other mental health problems and neurologic conditions, inflicts additional debilitation throughout their life course.⁽¹⁷⁾ Furthermore, the burden of XLH and associated health care needs vary with age. In childhood, long-term pharmacologic treatment may particularly be a burdensome issue to caregivers. Among adolescents, the psychological impact of XLH may become more apparent, while among adults, the need for surgery may emerge as a concern.⁽¹⁸⁾

Although there are international guidelines on XLH, not all of them provide clear guidance on transition of care. Moreover, the existing guidelines have so far focused only on the Western experience, which may not be applicable to the APAC region, where resource availability (i.e., medications, diagnostic testing, and multidisciplinary expertise) may be different. Furthermore, in majority of the current XLH guidelines, the lack of a validated methodology to obtain consensus recommendations constitutes another key unmet need.^(12,13,19-23)

Hence, we aimed to use the Delphi methodology to develop the most up to date XLH consensus recommendations on the diagnosis, multidisciplinary management and transition from pediatric to adult care, specifically tailored to the APAC setting.

2. Methods

2.1 APAC XLH Working Group

An APAC XLH Working Group was formed, comprising of a core expert panel of 15 pediatric and adult endocrinologists from nine APAC countries/regions (Australia, China, Hong Kong, Japan, Malaysia, Singapore, South Korea, Taiwan, and Thailand). Meanwhile, a voting group composed of 38 adult and pediatric XLH experts (including 15 core group and 20 additional XLH experts from 12 APAC regions, and 3 international XLH experts from the European Union) was also convened. In addition, the consensus recommendations were reviewed and endorsed by 17 local and regional endocrine, metabolic, and bone and mineral research societies, including the Asia Pacific Paediatric Endocrine Society (APPES), Australia and New Zealand Society for Paediatric Endocrinology and Diabetes (ANZSPED), the Australia and New Zealand Bone and Mineral Society (ANZBMS), the Chapter of Endocrinologists, College of Physicians (Singapore), the Chinese Society of Osteoporosis and Bone Mineral Research (CSOBMR), the Chinese Society of Paediatric Endocrinology and Metabolism (CSPM), the Endocrine and Metabolic Society of Singapore (EMSS), the Hong Kong Society of Paediatric Endocrinology and Metabolism (HKSPM), the Japanese Society for Bone and Mineral Research (JSBMR), the Japan Endocrine Society (JES), the Japanese Society for Pediatric Endocrinology (JSPE), the Korean Society for Bone and Mineral Research (KSBMR), the Korean Endocrine Society (KES), the Korean Society of Pediatric Endocrinology (KSPE), the Malaysian Endocrine and Metabolic Society (MEMS), the Taiwan Paediatric Association, and Taiwan Precision Children's Health Association.

2.2 Literature search, review and evidence rating

Initially, 16 research questions focused on key aspects of XLH diagnosis, multidisciplinary management and transition of care were drafted (**Supplementary Table S1**). To answer these questions, a comprehensive search was conducted on PubMed (MEDLINE) using a combination of relevant Medical Subject Headings (MeSH) and free-text terms (**Supplementary Table S2**). Studies [randomized controlled trials (RCTs), systematic reviews, observational studies, surveys, case series and case reports] published from January 2012–September 2021, with abstracts in English and conducted in children and adults with XLH, were considered for inclusion. Two authors (C.M. and W.X.) independently reviewed the search screening results and the data extracted from the shortlisted studies. The quality of evidence was assessed using the GRADE criteria and GRADEpro guideline development tool and rated as very low, low, moderate and high.⁽²⁴⁻²⁷⁾

2.3 Consensus building

Through an iterative editing process, preliminary draft statements were developed using the available evidence and subsequently presented and discussed by the APAC XLH Working Group members at an advisory meeting on 20 November 2021. During the meeting, the expert panel reviewed the literature and provided feedback to enable statement revision.

A Delphi technique was then applied to build consensus for each draft statement. A total of 38 XLH experts participated in two rounds of online voting, where the experts were asked to provide their agreement on the draft statement (on a scale of agree/disagree), with a provision to submit their comments for further refinement of the statements. Consensus was signified by an *a priori* agreement level of at least 70%.^(12,28) The statements that received comments during the first online voting were modified and rated again in the second round of online voting. The strength of the consensus was defined as ‘strong’ (>90% agreement), ‘moderate’ (70%–90%) or ‘weak or no consensus’ (<70%).

3. Results

The literature search yielded a total of 2,171 records (**Figure 1**). After title and abstract screening and de-duplication, 164 reports underwent full-text review for eligibility. Finally, 92 reports were included and used to draft 16 consensus statements. The statements were centered around three themes: screening and diagnosis, multidisciplinary management, and transition from pediatric to adult care. A final statement on medical education and training was also provided.

The majority of the included studies had an observational design (mostly cross-sectional). The rest were case reports or case series. The identified studies were similarly distributed among children and adults. In terms of outcomes, a high number of studies reported the prevalence of clinical, radiographic, and biochemical features of XLH while outcomes of the management of XLH were less often reported. Studies from the APAC region constituted <15% of the identified reports, most of which came from China. As with the general set, the APAC studies were retrospective cohort or cross-sectional studies, case reports, or case series.

Among the consensus statements, those on screening, diagnosis, and treatment of XLH had the largest body of high-quality supporting evidence. Meanwhile, statements on multidisciplinary referrals, monitoring, and follow-up were based on evidence of varying quality. The evidence supporting statements on the transition of XLH from childhood to adult care was limited. Nevertheless, the final statements reached a high percentage of consensus through the Delphi voting and were rated as strong recommendations (**Table 1**).

4. Discussion

4.1 Screening and diagnosis

Our recommendations for optimizing the screening and diagnosis of XLH in the APAC region are presented in **Table 2 (Statements 1–3)**. A diagnosis of XLH is established via a combination of clinical, radiographic, biochemical, and genetic characteristics. The age of onset of clinical features of XLH in majority of cases is between 1–2 years,^(29–34) but diagnosis is established later between 2–3 years of age.^(35–45) This is because of the variable clinical phenotype of XLH, which may often lead to misdiagnosis or delay in diagnosis.^(23,46) Early diagnosis of XLH leads to

prompt treatment and better outcomes.^(36,37,40,47) Hence, early recognition of renal phosphate wasting is essential (**Table 2, Statements 1A and 1B**).

4.1.1 Clinical and radiologic features

The most common initial manifestations of XLH include short stature, bone deformities, and radiologic signs of rickets^(29-32,34,35,39) (**Table 2, Statement 2A**). These clinical and radiologic features should prompt timely and appropriate referral for biochemical testing, early confirmation of the diagnosis, and initiation of treatment. Genetic testing is not mandatory to confirm the diagnosis, given the resource constraints in some APAC countries.

Reduced growth velocity and short stature (i.e., height z-score below -2 standard deviations) are found in 33–92% of children with XLH.^(35,36,38-43,48) Although children with XLH are born with average length, growth velocity begins to deviate from the norm at 6 months of age, and reduced growth is evident by 1 year and persists throughout childhood until final height.^(32,49) Short stature is thus observed in over 50% (56%–95%) of adults with XLH.^(36,42,50-52) The short stature found in XLH may be disproportionate; specifically, leg length is shorter than trunk, leading to a substantially increased sitting height index.^(45,52) The short stature is XLH may be misdiagnosed in some cases as achondroplasia, the most common form of skeletal dysplasia.⁽⁴⁶⁾

The majority of patients with XLH have lower limb deformities.^(32-34,36,39-41,43,53) Genu/coxa varum or valgum is seen in over 90% of most cohorts.^(32,36,39,41,53) These deformities may be associated with intoeing or an unstable or abnormal gait and cause delayed onset, difficulty, or pain with walking and early fatigue.^(29,30,32,33,54-56) Radiographic evidence of rickets is observed in 100% of XLH cohorts before treatment and in over 70%, despite conventional treatment.^(32,37-39,41) Typical findings on skeletal X-ray include widened and cupped metaphyses seen at the distal end of the radius, ulna, femur and tibia.^(32,41,57,58) The major differential diagnosis for XLH is nutritional rickets that occurs due to vitamin D and/or dietary calcium deficiency.^(12,54,55) The severity, chronicity, progression, or persistence of signs and symptoms despite Vitamin D and calcium supplementation may help differentiate between the two conditions and suggest XLH as the more likely diagnosis.^(12,54,55)

Dental pathology (e.g., gingivitis, periodontitis, dental malposition, dental abscess) is common among children with XLH and has been observed in up to 100% of cases.^(33,35,38,40,43,52,53,59,60) In XLH, dental abscesses are often recurrent and may be associated with fistula formation and occur without dental decay or history of injury.^(38,43) Patients with XLH may present with delayed eruption of dentition or premature loss of teeth.^(29,30,32,56,61) Early loss of dentition and severe dental caries are also noted in hypophosphatasia, a rare inherited metabolic disorder. Differential diagnosis should be considered based on biochemical findings; hypophosphatasia is associated with reduced serum and bone alkaline phosphatase (ALP) activity,⁽⁶²⁾ while XLH in children is associated with persistently elevated ALP levels.⁽¹²⁾

Other skeletal signs in children with XLH include enlarged wrists (46%), rachitic rosary (9% in treated cases and up to 38% in untreated cases), rib eversion (60%), pectus carinatum (47.7%), bracelet signs (64.6%), and skull malformations (7.9–54%).^(33,39,41,43,63) The latter include frontal bossing, square head, scaphocephaly, and craniosynostosis.^(29,32,43,53,63,64) Specifically,

craniosynostosis may be an early sign of XLH in infancy, presenting with an abnormal head shape.^(64,65) About 10% of children with XLH also have a concomitant Chiari malformation,⁽⁴³⁾ characterized by extension of the brain tissue through the foramen magnum. While most cases are asymptomatic, compression of the lower brain stem and upper spinal cord may cause symptoms, including severe headache, neck pain, and a myriad of motor, sensory, respiratory and neurological complications that may result in syringomyelia necessitating surgery.^(12,13,23) Aside from the cranium, bony affectation can also lead to the formation of Harrison's groove/sulcus at the lower end of the rib cage, while rachitic rosary develops at the costochondral junctions.^(12,66)

In adults with XLH, pseudofractures are noted in 29%–52% of cases.^(14,51,59) Other musculoskeletal manifestations frequently seen in adults are enthesopathies (33–100%) and osteoarthritis (55–80%), which become more prevalent beyond 30–40 years of age.^(14,37,51,52,59,67) Accordingly, pain is reported in almost 100% of adults with XLH, and muscle weakness in 60% of cases, along with joint stiffness and impaired mobility or physical function (e.g., using the 6-minute walk test [6MWT]).^(14,16,23,67) Dental abscesses are reported in about 82% of adults with XLH.⁽²³⁾ Moreover, most adults with XLH (~50–79%) have a history of orthopedic surgery, most commonly long bone osteotomy.^(14,37,51-53,59)

4.1.2 Biochemical features

Hypophosphatemia with renal phosphate wasting is a biochemical hallmark of XLH. Regardless of age, almost all XLH patients (95–100%) display low serum phosphate levels.^(32,36-38,41,42,44,60) However, hypophosphatemia may not be apparent in the first 3–6 months of life and may be missed due to varied age-specific reference values and normal phosphate levels in some infants.^(12,19,23) Renal phosphate wasting is ideally assessed by determining the tubular maximum reabsorption of phosphate per glomerular filtration rate (TmP/GFR). Age-related reference ranges are available for this parameter, which is computed from fasted, second-morning, paired plasma and urine phosphate and creatinine levels.⁽⁶⁸⁻⁷¹⁾ The TmP/GFR is reduced in almost 100% of XLH patients.^(38,42,44) Nevertheless, XLH should be differentiated from non-selective causes of renal phosphate wasting (i.e., Fanconi syndrome) that present with other distinctive features such as bicarbonate and uric acid wasting, glucosuria, aminoaciduria, and low-molecular-weight proteinuria.^(12,13,19,22,23)

Alkaline phosphatase, a marker of bone turnover, is elevated in association with rickets and osteomalacia. Because bone-specific ALP constitutes ~90% of total ALP in children and only ~50% in adults, total ALP may be used for children while bone-specific ALP is recommended for adults.^(12,13,19,22,23) In some settings, bone-specific ALP may not be available or commonly used.⁽¹³⁾ If the assay for bone-specific ALP is not available, the traditional heat fractionation of ALP may be used.^(72,73) As with phosphate levels, ALP follows an age-based reference range and though it may be normal in the first few months of life in some patients with XLH,^(13,74) elevated ALP is demonstrated by 83%–100% of children (over 1 year of age) with XLH.^(32,37,38,41,42)

The other biochemical parameters observed in most patients with XLH, and their reported prevalence rates are normal serum calcium levels (89.2–100%),^(37,41,42,60) normal serum vitamin

D levels (81.3–100%),^(38,41) normal or mildly increased serum parathyroid hormone (PTH) levels (54.4–100%),^(33,41,42) and inappropriately normal or elevated intact fibroblast growth factor-23 (iFGF-23) levels (74.2–100%).^(32,33,36,37) iFGF-23 testing is not widely available, and results should be interpreted with caution due to lack of standardization and potential influence by treatment.^(4,11)

25-hydroxy vitamin D levels should be normal in XLH, unless affected by factors such as sun exposure, nutrition, maternal vitamin D status and comorbid renal conditions. While the levels of the active form, 1,25-dihydroxyvitamin D, may be inappropriately low in the setting of hypophosphatemia.^(38,41) Notably, in Asian cohorts, due to the overall high prevalence of nutritional rickets due to vitamin D deficiency, XLH patients may also have concurrent vitamin D deficiency (43.6–59.8%), which may in turn mask the diagnosis of XLH.^(33,75) With regard to PTH levels, XLH patients have higher levels versus healthy controls, although when compared with calcium-deficient rickets, these levels are still within the upper bounds of normal or only slightly elevated.^(12,44)

4.1.3 Genetic features

Genetic testing confirms the diagnosis of XLH and facilitates genetic counselling of the patient and family members.^(30,31) Single-gene *PHEX* sequencing suffices as the first step in genetic analysis, because it detects the most common cause of hypophosphatemic rickets.⁽⁷⁶⁾ A confirmed pathogenic *PHEX* mutation is found in ~90–100% of clinically diagnosed patients.^(37,53) In case genetic testing is not available, a positive family history of XLH is generally accepted as supportive of the diagnosis.⁽⁵³⁾ About 21%–82% of XLH patients have a family history of hypophosphatemic rickets and may be identified via family screening.^(35,37,39,40,43,44,53) The transmission consistent with XLH is X-linked dominant inheritance: from male parent to female offspring or from female parent to 50% of male/female offspring. No genotype-phenotype correlation has been established.^(32,33,40,60,75)

4.2 Multidisciplinary management

Our recommendations for optimizing the multidisciplinary management of XLH in the APAC region are shown in **Figure 2 (Statement 4)** and **Tables 3–8 (Statements 5–12)**. The multitude of clinical, radiographic, and biochemical manifestations of XLH warrant multidisciplinary care. The goals of management should be tailored to the clinical presentation and the patient's age (**Figure 2, Statement 4**).^(12,17,18,77)

The primary management goal in children with XLH is to promote optimal growth and global development, early correction of deformities and monitoring for XLH complications and its treatment. When children with XLH enter adolescence, there is an added need to ensure that they are prepared for transition into the adult world, both medical and the wider community. Throughout childhood and adolescence, it is essential that the young person with XLH is supported at school and has full access to the educational curriculum.

In adult life, issues such as reproductive options, and obstetric care should be addressed as a part of holistic care. Later, complications such as fractures, arthritis and dystrophic calcification need to be addressed. Support needs to be provided in the workplace to ensure that the adult with XLH is able to achieve and maintain gainful employment. Across all ages, the overarching principles of care include early multidisciplinary care, early initiation and adherence to treatment, and early detection of complications. Psychosocial and emotional well-being should also be considered at all stages of development, in efforts to improve overall QoL.^(13,49,77-80)

4.2.1 Pharmacologic treatment

Table 3 (Statements 5A–5E and 6) summarizes our recommendations for the treatment of XLH in the APAC region.

4.2.1.1 Conventional therapy

The conventional medical therapy for XLH is oral phosphate supplementation, combined with active vitamin D (i.e., calcitriol or alfacacidol) (**Table 3, Statement 5A**). Real-world studies among children and adults have demonstrated the association of conventional therapy with improved outcomes in XLH, such as: 1) clinical outcomes (higher height z-scores), 2) radiographic outcomes (fewer skeletal events), and 3) dental health outcomes (lower carious index, lower attachment loss, fewer endodontically-treated or absent teeth).^(32,36,37,81-83)

Among children with XLH, early initiation of conventional therapy has been associated with improved growth parameters. A retrospective cohort study in the UK (N=23) showed that the most recent height measurements were significantly better among children who started conventional therapy before one year of age compared with those who started later (median height standard deviation score -0.7 vs -2.0, $p=0.009$).⁽⁴⁷⁾

Accordingly, international and national guidelines recommend starting combination therapy with oral phosphate and active vitamin D in children as soon as the diagnosis of XLH is established. The initial goal involves healing of rickets in affected children. Treatment is also aimed at reducing skeletal deformities, precluding surgery, facilitating growth, alleviating bone pain, and improving dental health. The generally recommended starting doses in children are 20–60 mg/kg body weight of elemental phosphorus given 4–6 times daily, and 20–40 ng/kg body weight of calcitriol given in two doses per day or 30–50 ng/kg body weight of alfacacidol given once daily.^(12,13,19,22,23,84)

Conventional therapy with oral phosphate and 1,25-dihydroxy vitamin D₃ in a prospective study in 16 symptomatic adults with XLH has been found to be associated with a significant increase in serum phosphate, and reduction in osteoid thickness and osteoid volume. The reduction in osteoid volume correlated with a significant reduction in symptomatic bone/joint pain.⁽⁸⁵⁾ In another prospective, observational study in 34 adults with XLH, continual treatment of hypophosphatemia with vitamin D and phosphate was associated with improvement in periodontal health.⁽⁸¹⁾ Apart from skeletal and oral health outcomes, conventional therapy in adults has been associated with improvements in mental health outcomes, such as better mental component scores in the 36-item Short Form survey (SF-36).^(14,79) However, the evidence of

clinical benefit is insufficient to support conventional treatment in asymptomatic adults.^(52,79) Hence, contemporary guidelines recommend initiating or continuing combination therapy with oral phosphate and active vitamin D only in symptomatic adults, specifically those with dental problems, musculoskeletal pain, pseudofractures, elevated ALP, or planned orthopedic or dental surgery.^(12,13,22) In general, the recommended doses of conventional treatment for adults are 750–2,000 mg of elemental phosphorus divided into 2–4 doses daily, and 0.50–0.75 µg of calcitriol or 0.75–1.5 µg of alfacacidol daily.^(12,13,22,23)

Despite the clinical benefits of conventional treatment, the multiple daily doses required may disrupt routine activities and become burdensome to patients. Along with the medications' unpleasant taste and potential for adverse effects, these factors may limit adherence to conventional therapy (**Table 3, Statement 5B**).^(16,19,86) Key adverse events include: 1) gastrointestinal discomfort (e.g., diarrhea, bloating) in 56% of patients, 2) hyperparathyroidism in 17–47.5% of children and 15.6–45% of adults, and 3) nephrocalcinosis in 15.6–25% of adults and 11.3–68% of children.^(14-16,35,37,39,40,43,47) Nephrocalcinosis results from the promotion of hypercalciuria by conventional therapy and has been associated with longer treatment durations and higher treatment dosages.^(37,39) Additionally, presence of nephrolithiasis has been documented in 2%–14% of XLH patients,^(16,37) and impairment of renal function in 7.1% of children⁽¹⁵⁾ and 8%–9.5% of adults with XLH.^(15,16) Furthermore, hypertension has been reported in treated XLH children with a significant association with hyperparathyroidism, which is one of the key side-effects of conventional therapy.⁽⁸⁷⁾

Commercial availability of oral phosphate solutions in the APAC region is limited. In many APAC countries, oral phosphate solutions need to be prepared in private pharmacies. Therefore, accessibility is curtailed, especially in rural or remote areas. Furthermore, oral phosphate supplementation and/or active vitamin D are not reimbursed under select national health insurance (NHI) schemes in some APAC regions. An impetus therefore exists for national governments and health agencies to ensure access to standard conventional therapy formulations for all children with XLH and all symptomatic adults with XLH in the APAC region (**Table 3, Statement 5C**).

Notwithstanding, the health-related quality of life (HRQoL) of XLH patients remains poor even with conventional treatment, indicating the need for better treatment options.⁽⁸⁸⁾

4.2.1.2 Burosumab

Burosumab is a fully human monoclonal antibody against FGF23. In 2018, the European Medicines Agency (EMA) approved its use in EU for XLH in children from the age of 1 year, and adolescents with a growing skeleton. In the same year, the Food and Drug Administration granted approval of its use in children aged 1 year and above and subsequently also granted approval for patients 6 months of age and older. The EU approval was expanded further in 2020 to include all adolescents and adults.^(13,89,90)

The efficacy of burosumab as treatment for pediatric XLH has been demonstrated in an international phase III RCT among children aged 1–12 years old (N=61). The study revealed the superiority of burosumab over conventional therapy at 64 weeks in terms of: 1) a greater increase

in height (mean difference 0.14, $p < 0.05$); 2) a greater decrease in rickets severity by Radiographic Impression of Change score (mean difference 1.0, $p < 0.0001$) and by Rickets Severity Score (RSS; mean difference -1.2, $p < 0.0001$); and 3) a greater decrease in lower limb deformity (mean difference 1.0, $p < 0.0001$). Significant improvements in biochemical parameters (i.e., serum phosphorus, TmP/GFR, ALP), pain interference scores, and 6MWT scores have also been reported. According to a *post-hoc* subgroup analysis of this trial, the improvements with burosumab versus conventional therapy, specifically in terms of the biochemical parameters, are seen both in children aged 1–<5 years and those aged 5–12 years.^(48,57,91)

Most contemporary guidelines recommend initiation of burosumab in patients who have – (1) rickets that is radiographically proven and refractory to conventional therapy, or (2) intolerance or complications with conventional therapy. The recommended starting dose of burosumab in children is 0.8 mg/kg body weight given subcutaneously every 2 weeks. Conventional therapy must be discontinued two weeks prior to burosumab therapy, and the child should have a serum phosphate level below the lower end of the age adjusted reference range.^(12,13,19,21–23)

Among adults, the clinical benefits of burosumab therapy over placebo have also been illustrated by RCTs.^(50,51,67,92) In a large-scale, international, phase III RCT among adults with XLH (N=134), the burosumab group had a significantly higher proportion of subjects achieving a normalization in serum phosphate versus the placebo group (94.1% vs 7.6%, $p < 0.001$) at 24 weeks, as well as greater improvements in fracture/pseudofracture healing, other biochemical parameters, and patient-reported outcomes (PROs).⁽⁵⁰⁾ An extension of this study revealed persistent improvements with burosumab beyond 24 weeks, particularly in terms of PROs (pain, stiffness, fatigue) and functional capacity.^(51,67) However, available evidence of efficacy versus conventional therapy is limited and hence, current guidelines recommend burosumab therapy for adults with refractory symptoms or those experiencing complications with conventional therapy.^(12,13,22,23) In adults, the recommended initial dose of burosumab is 1.0 mg/kg body weight given subcutaneously every 4 weeks.^(12,22,23) As with children, conventional therapy should not be used concurrently with burosumab therapy.^(12,22) Our recommendations for burosumab therapy in the APAC region can be found in **Table 3, Statement 5D**.

In contrast to conventional therapy, burosumab is not associated with adverse effects such as nephrocalcinosis and hyperparathyroidism.^(93,94) In clinical trials of burosumab therapy, nephrocalcinosis did not develop among previously unaffected patients while substantial progression was not detected in nearly all of those with baseline affection.^(50,57–59,63,95–97) Nevertheless, adverse events with at least a possible relation to burosumab have been reported in 38.5–59% of children and 64–71.4% of adults in clinical trials.^(57,59,63,95) The most common adverse effect was injection site reaction (e.g., erythema, urticaria), which was mostly mild, limited to the skin, and resolved in a few days.^(50,57–59,63,95) Based on follow-up studies of RCTs, the safety and tolerability of burosumab are sustained through ~120–160 weeks of treatment.^(96,97)

Apart from a small-scale phase III/IV, single-arm trial in Japan (N=15),⁽⁹⁷⁾ the studies evaluating burosumab therapy have involved predominantly Western populations. In a few international

RCTs, Asian subjects have composed only ~13–15.7% of study participants.^(48,50,51,57,67) More research conducted in the APAC region is warranted to formulate more specific guidelines on burosumab therapy directed towards APAC patients. Currently, burosumab is not consistently available across the APAC region (**Table 3, Statement 5E**). In APAC countries where burosumab is available, accessibility is restricted by high costs. If approved, coverage under the NHI scheme of APAC countries is expected to increase access of XLH patients to burosumab therapy. For instance, burosumab has recently been added into the Pharmaceutical Benefits Scheme of Australia, whereby the government would subsidize its costs for both children and adults with XLH.⁽⁹⁸⁾

4.2.1.3 Growth hormone

Current guidelines do not recommend treatment of XLH children with short stature with recombinant human growth hormone (rhGH)⁽²³⁾ due to the lack of high-quality evidence supporting its use.⁽⁹⁹⁾ However, in a recent retrospective longitudinal cohort study, two years of rhGH therapy was associated with improvement in final height in 34 XLH children with growth failure despite conventional treatment.⁽¹⁰⁰⁾ In another prospective, longitudinal, observational cohort study, addition of rhGH to conventional or burosumab therapy was noted to be safe and resulted in catch-up growth in 13 children with XLH.⁽¹⁰¹⁾ Due to the low sample size and observational nature of these studies, no clear recommendation can be made for the use of growth hormone in children with XLH and short stature. Well-designed RCTs in future may help establish the role of growth hormone for the treatment of children with XLH.

4.2.1.4 Pregnancy and lactation

Published literature surrounding XLH in pregnancy is sparse (**Table 3, Statement 6**). In a report from a single center, conventional therapy was continued among stable pregnant women with XLH although it was not initiated in those not previously undergoing treatment. Overall, there was a small increase in urine calcium: creatinine ratio in patients on conventional treatment, however, there was no significant association of this finding with nephrocalcinosis. All pregnant women with XLH on conventional therapy were monitored for serum calcium and urinary calcium: creatinine ratio, with required treatment modifications. The rate of caesarean section was high (75%), primarily due to breech presentation and the clinician's/patient's preference owing to the potential complications associated with delivery in this patient cohort.⁽¹⁰²⁾

No prior consensus or strong recommendation has been established regarding conventional therapy for pregnant or lactating patients with XLH.^(12,13,22,23) Nevertheless, pregnancy and lactation are critical periods for bone health, as bone mineralization disorders may also exacerbate during pregnancy.⁽¹⁰³⁾ Therefore, intensification of monitoring under these circumstances is essential. More studies in the future may help in optimizing the guidance on conventional treatment and monitoring of pregnant and lactating women with XLH.

There are no or limited data on the use of burosumab in pregnancy.^(89,90) Similarly, no information is available regarding presence of burosumab in breastmilk or its effects on the breastfed infant.^(89,90) The EMA labelling of burosumab does not recommend its use during pregnancy and in women of childbearing potential not using contraception.⁽⁸⁹⁾ The post-

authorisation safety study (PASS) is a retrospective and prospective cohort study that will utilize the data from the international XLH registry to evaluate the frequency and outcomes of pregnancies in female XLH patients receiving burosumab.⁽¹⁰⁴⁾

4.2.2 Multidisciplinary referral

The recommended multidisciplinary referral for XLH patients is shown in **Table 4 (Statements 7 and 8)**. The multidisciplinary team managing XLH cases is frequently led by a metabolic bone specialist or an endocrinologist (pediatric or adult). In some settings, the team may be steered by a pediatrician or internist with special interest in XLH or a nephrologist (pediatric or adult).⁽⁵³⁾ In any case, the lead physician should facilitate the development of a multidisciplinary management team including at least orthopedics, dentistry, rehabilitation medicine and allied health for both children and adults with XLH.

About 50–80% of children and adults with XLH will undergo at least one orthopedic procedure, warranting the presence of an orthopedic surgeon in the multidisciplinary team.^(16,37,43,53) Among children, surgeries commonly performed include hemi-epiphysiodesis (14.3–19%) during the growth phase and osteotomy (17–33%) when growth has ceased.^(15,16,39) Expectedly, more frequent osteotomies (34.4–65.5%) and less hemi-epiphysiodesis (6%) are seen in adults.^(15,16,82) Adults may also need to undergo surgical repair of fractures.^(16,102) Moreover, because osteoarthritis is prevalent in adult XLH, surgical procedures also include knee and hip replacements.^(14,16,102) For similar reasons, referral to a rheumatologist may be necessary.

The propensity of those with XLH for developing oral health issues requires the involvement of dental services in the management team. Endodontic treatment may be necessary in both children and adults;^(15,16,36,81) a history of root canal surgery is found in up to 72% of adults with XLH.⁽¹⁶⁾ Meanwhile, dental extraction is performed in about one third of children and half of adolescents and adults with XLH.^(63,102)

Rehabilitation in XLH, which aims to improve daily function, may involve physiotherapists, occupational therapists, physiatrists, or rehabilitation medicine specialists. Assistive devices for mobility (e.g., wheelchair, walking device) are used in both pediatric and adult XLH patients with varying prevalence (11.5–100%).^(14,15,37,105) Additionally, 10.2–57.4% of XLH patients undergo physical therapy or physiotherapy.

Due to comorbidities such as Chiari malformation, craniosynostosis, and syringomyelia, 3.3–9% of children and 2.6–6.3% of adults would need neurosurgery (e.g., craniotomy, craniectomy) warranting referral to a neurosurgeon.^(15,16,102,106) Moreover, hearing impairment or loss may be found in 5.7–55% of children and adults with XLH, necessitating a referral for formal audiologic assessment starting 8 years of age.^(12,15,16,53,102) Contemporary guidelines also recommend referrals to geneticists and genetic counsellors for genetic counselling, psychologists for psychosocial support, rehabilitation specialists for supporting access to educational curriculum and workforce participation, and dieticians for nutritional advice.^(12,13,19,21–23) Among patients planning for pregnancy, a referral to a gynecologist or obstetrician should be made in addition to a genetics consult.

4.2.3 Monitoring and follow-up

Monitoring and follow-up is an important aspect of XLH management and should reflect the goals of multidisciplinary management at each life stage: childhood (**Table 5, Statement 9**), adolescence (**Table 6, Statement 10**), and adulthood (**Table 7, Statement 11**).

The frequency and interval of follow-up should be individualized. However, in general, children and adolescents should be seen every 3 months, especially during infancy and puberty, wherein growth is most rapid. Adults require less frequent visits (every 6–12 months). Our recommendations on follow-up evaluations and testing frequencies may vary from the international guideline recommendations and reflect the minimum standard, accounting for resource limitations in some APAC countries.

4.2.3.1 Clinical evaluation

Anthropometric measurements, such as height or length and weight, are essential components of each visit at any age. A higher body mass index (BMI) in XLH has been associated with gait deviations as well as higher counts of enthesopathies.^(78,82) Patients with XLH also potentially have a higher prevalence of obesity versus the general population.⁽¹⁷⁾ In children, height z-scores and growth velocity should be determined, having demonstrated response to or correlation with treatment in previous literature.^(57,83)

Head circumference, skull shape and neurologic symptoms (e.g., headache) should be assessed at each visit during childhood, to ensure that craniosynostosis or Chiari malformation are detected as early as possible.⁽¹⁰⁶⁾ Regardless of age, limb deformities should be monitored during each visit, and intermalleolar and intercondylar distance must be measured.⁽¹⁰⁷⁾ Additionally, the blood pressure should be monitored, in line with some evidence pointing to a higher prevalence and early onset of hypertension in XLH versus the general population, while on conventional medical therapy.^(87,108)

Pain and joint stiffness are symptoms known to respond to treatment and should be elicited during consultation. While previous studies involving children have used the Patient-Reported Outcomes Measurement Information System (pain interference, physical function mobility, fatigue),⁽⁴⁸⁾ studies involving adults have applied a variety of PROs validated for XLH, including the Brief Pain Inventory Short Form (pain severity and interference), and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC; pain, stiffness, physical function).^(50,51,67) PROs such as the WOMAC pain and stiffness score also correlate with counts of enthesopathies and presence of fractures.⁽³⁷⁾

For patients aged ≥ 5 years, physical function may be evaluated using parameters of the 6MWT (e.g., total distance, percentage of predicted distance), which have shown improvement with treatment in prior studies.^(51,57,67) The Activities-Specific Balance Confidence (ABC) scale may also be utilized, wherein lower scores correlate with fear of falling while higher scores correlate with greater range of motion.⁽¹⁰⁵⁾ Because of potential muscle-bone cross talk,⁽¹⁰⁹⁾ monitoring muscle function via handgrip strength or the sit-to-stand test may also be useful and considered as per the local resource constraints.

Other questionnaires for health-related quality of life (SF-36, Health Assessment Questionnaire, Routine Assessment of Patient Index 3) have not been validated in XLH but have illustrated treatment response, as well as correlation with deformities, dental health, and enthesopathies in past studies.⁽⁷⁹⁾

4.2.3.2 Biochemical evaluation

Biochemical assessments are performed regularly in XLH to monitor disease activity, adjust treatment, and balance therapeutic response and safety. Accordingly, the frequency of testing is higher among patients who are symptomatic or on pharmacologic therapy (i.e., children) and lower among asymptomatic patients not receiving treatment (i.e., adults).

Total ALP in children and bone-specific ALP in adults are markers of bone turnover and elevated with rickets, and osteomalacia, and should be determined regardless of treatment status or type of treatment. While total ALP levels have improved among children treated with burosumab in clinical trials,⁽⁵⁷⁾ bone-specific ALP levels have been reported to increase from baseline after initiation of burosumab in adults, followed by gradual attenuation of this effect over time.^(50,51) Among those receiving conventional therapy, ALP levels can be used to titrate treatment dosages.^(84,86,110) Most centers perceive ALP normalization as the primary biochemical parameter indicating satisfactory treatment.⁽⁵³⁾ Although ALP levels ideally should be kept within the normal range, some believe levels below 1.5-times the upper limit of normal for age are acceptable.⁽⁵³⁾

Monitoring of serum phosphate is important during treatment of XLH. The goal of treatment with burosumab is to achieve phosphate homeostasis. Hence, serum phosphate levels should be monitored and used to adjust the dose of burosumab.^(50,51,57,58,63,92,95) On the other hand, conventional therapy will not restore phosphate levels and is not intended for normalizing phosphatemia.^(12,13,19,23)

Other biochemical tests conducted to detect potential adverse effects of pharmacologic therapy include: blood levels of PTH and calcium; 25-hydroxyvitamin D or 1,25-dihydroxyvitamin D; urinary excretion of calcium (i.e., urine calcium: creatinine ratio); and serum creatinine for calculation of GFR.^(35,37,40,43,47,50,51,53,57-59,92,95,102) Phosphate supplementation may lead to hypocalcemia and stimulate parathyroid cells, causing secondary and eventually tertiary hyperparathyroidism.^(111,112) Whilst active vitamin D may potentially cause hypercalciuria and consequent nephrocalcinosis,⁽¹¹³⁾ with or without renal impairment. Burosumab therapy, which can increase blood levels of 1,25-dihydroxyvitamin D, also has the potential to cause biochemical derangements downstream of this pathway.^(50,51,57-59,92,95)

4.2.3.3 Radiologic evaluation

Serial x-rays are recommended to monitor severity of rickets in children and adolescents with XLH. For instance, the Rickets Severity Score based on wrist and knee radiography is not only known to improve with treatment but also correlates with height z-score, severity of dental abscesses, and PTH levels.^(37,38,57) These x-rays can also be used to determine bone age and assess growth potential, especially among children with short stature.

To minimize radiation exposure, previous guidelines recommend that other x-rays (e.g., long bone radiography) be reserved for specific indications, including persistent lower limb deformities and need for orthopedic surgery (e.g., for fractures).^(12,13,22,23) Monitoring with x-rays in clinical trials have shown that lower limb deformities and fractures/pseudofractures respond to burosumab therapy.^(50,51,57)

Dual-energy x-ray absorptiometry (DXA) is a common diagnostic procedure to assess bone mineral density (BMD) and the associated risk for fractures among older adults and post-menopausal women with XLH.⁽¹¹⁴⁾ In children and adults with XLH, BMD is higher than healthy controls by DXA.^(115,116) However, this finding is attributable to extra-skeletal spinal calcifications and enthesopathies, exhibited by adults, who then require this imaging more than children.^(115,116)

Meanwhile, renal ultrasound has been the monitoring tool utilized in clinical trials and real-world studies to evaluate the adverse effects of pharmacologic therapy in XLH.^(35,37,40,47,50,51,53,57-59,63,92,95,102) Accordingly, it is the preferred screening method for nephrocalcinosis and should be performed annually.

4.2.3.4 Multidisciplinary monitoring

Because of the burden of dental disease in XLH, twice-yearly dental evaluations are recommended, regardless of age.^(35,38,40,43,52,53,59) Monitoring of other complications (i.e., orthopedic, craniofacial, neurosurgical, audiologic) should be individualized based on initial results, input from specialty referral, and availability of resources. Genetic counselling should be considered not only at the time of diagnosis but also during transition to adult care and during family planning. Moreover, regular psychosocial assessments should be performed in XLH patients across the life stages. Although these services may not be available in all clinical settings across the APAC region, the psychological health of children and adults with XLH must be considered and managed appropriately. In children and adolescents, checking for developmental milestones and performance in school should be a routine part of the health visit.^(18,79)

4.2.4 Role of telemedicine

A recommendation on the role of telemedicine in optimization of XLH treatment and care is provided in **Table 8 (Statement 12)**. The COVID-19 pandemic and corresponding public health interventions (e.g., lockdown) caused a disruption of regular health services, including reduced hospital admissions and suspended outpatient operations. In Italy, telemedicine became an integral component of the management of XLH patients during the pandemic. Physicians communicated with patients and their caregivers through e-mail, phone calls, or social media. Some clinical parameters (e.g., anthropometrics, adverse events) required remote monitoring through photographs and videos. PROs (e.g., WOMAC) were regularly administered as appropriate.⁽¹¹⁷⁾

In some APAC countries, even before the pandemic, certain areas may already be geographically disadvantaged while others may lack centers of XLH expertise, and telemedicine may be essential for health care delivery in such countries/regions. Utilization of e-health technologies

has been reported to have advantages such as increased patient awareness of disease, better patient-physician relationship, and reduced transportation and work burden. While telemedicine may help reduce visits that do not need blood tests or imaging and may be useful in geographically challenged regions, it may not completely replace in-person visits, especially when physical examination, imaging, blood tests, and multidisciplinary monitoring and referral are required in XLH.⁽¹¹⁷⁾

4.3 Transition of care from childhood to adulthood

Our recommendations for optimizing the transition of care of adolescents with XLH in the APAC region are shown in **Figure 3 (Statement 13)**, **Figure 4 (Statement 14A)**, **Table 9 (Statements 14B and 14C)**, and **Table 10 (Statement 15)**. All adolescents with XLH have the need for a carefully planned healthcare transition. In general, the healthcare transition can be divided into various stages: initiation and assessment of readiness for transition, proceeding with transition, and successful transition to adult care. Various models of care have been built for more common diseases, identifying the determinants of transition outcomes (e.g., family and psychosocial support, effective communication). However, usual transition models may have restricted applicability to rare genetic diseases due to several reasons: 1) limitations in access to a variety of specialists, 2) the consequent lack of knowledge of disease, and 3) the influence of long-term caregiver experience on the expectations of the adolescent.⁽²⁰⁾

While the evidence surrounding transition of care for XLH patients is lacking, overarching principles from transition models for other rare diseases remain indispensable in XLH. As with these other illnesses, timelines in XLH should be specified, consisting not only of well-defined goals for each transition stage (**Figure 3, Statement 13**) but also clear and distinct roles and responsibilities for all involved stakeholders (**Figure 4, Statement 14A**). Patient education, geared towards increasing awareness, independence, and self-advocacy, is an encompassing theme across the entire course of transition, as is the provision of continuous psychosocial support.

In the APAC region, the cut-off age for transition of care has a wide range (14–18 years) across countries. Generally, introducing transition of care to families should begin 2–4 years before the actual initiation of care transition. Involving the child in these discussions should be considered as early as the psychosocial status of the patient permits. However, the age at which these talks of transition commence also differs among APAC countries, varying based on the culturally accepted age when children assert their independence from their parents. Notwithstanding, timelines should be individualized according to the patient's readiness for transition of care. Additionally, in some countries or settings, a provision should be made to allow the pediatric XLH expert continue the follow-up of patients with XLH, while facilitating remote consultation with adult XLH experts, if feasible to ensure continuity of care.

The infrastructure that supports the age-appropriate and seamless transition involves transition questionnaires and transition clinics (**Table 9, Statements 14B and 14C**), as well as transfer letter checklists (**Table 10, Statement 15**). Transition questionnaires such as the TRxANSITION™ Index and the STARx Questionnaires have been validated in XLH.⁽²⁰⁾

However, translations of these questionnaires to APAC languages are limited.⁽¹¹⁸⁾ Meanwhile, the Transition Readiness Assessment Questionnaire (TRAQ) has been translated into more APAC languages but are not specific to XLH (**Table 9, Statement 14B**).⁽¹¹⁹⁾

Although establishing a transition clinic will optimize the transfer of care (**Table 9, Statement 14C**), this set-up may not be feasible in resource-limited APAC settings. Thus, an XLH transition clinic may alternatively be enveloped under a more general clinic for bone and metabolic disorders. These clinics may meet once to twice per year, depending on availability of resources. The minimum requirement for a transition clinic will be the simultaneous presence of a pediatric and adult endocrinologist. However, enlisting the help of a case manager (e.g., nurse practitioner) is ideal to provide a consistent connection between the patient and the pediatric and adult providers, even beyond transition clinic days.

Lastly, a transfer checklist containing details of care (e.g., disease-specific information, physician data) facilitates a smoother transition between providers.⁽²⁰⁾ While such checklists should aim to be exhaustive, they should also be individualized and tailored to the APAC setting (**Table 10, Statement 15**).

4.4 Medical education, training, and research

Continuing medical education and training for healthcare providers of XLH patients are a fundamental component of optimizing XLH care in the APAC region (**Table 11, Statement 16**). These initiatives are intended to address the limited number of multidisciplinary experts in APAC countries, as well as to extend the reach of their expertise towards remote areas with limited access to XLH care. Conducting focus group meetings among clinicians involved in the care of XLH patients, establishing ‘centers of excellence’ across the APAC region and utilizing telemedicine are potential means to achieve this goal. Additionally, establishing an APAC XLH registry in collaboration with key regional or local societies will help create a robust database to facilitate potential research in future. Furthermore, generation of local data pertaining to response to treatment of XLH, and complications will help in improving the utilization of newer treatment approaches such as Burosumab and optimizing the management of XLH in the region.

5. Conclusion

We conducted a comprehensive review of the existing literature on XLH and presented 16 consensus statements addressing the screening and diagnosis, multidisciplinary management, and transition of care of XLH from childhood to adulthood. Ultimately, optimized care for XLH patients requires prompt identification and early diagnosis; timely multidisciplinary care with regular monitoring and follow-up; and a seamless transfer of care through the coordinated effort of all stakeholders. Based on the best available evidence, we outlined specific guidance for clinical practice in APAC settings. Nevertheless, more APAC research is warranted to refine future recommendations.

6. Acknowledgments

We thank the Asia Pacific Paediatric Endocrine Society (APPES), Australia and New Zealand Society for Paediatric Endocrinology and Diabetes (ANZSPED), the Australia and New Zealand Bone and Mineral Society (ANZBMS), the Chapter of Endocrinologists, College of Physicians (Singapore), the Chinese Society of Osteoporosis and Bone Mineral Research (CSOBMR), the Chinese Society of Paediatric Endocrinology and Metabolism (CSPPEM), the Endocrine and Metabolic Society of Singapore (EMSS), the Hong Kong Society of Paediatric Endocrinology and Metabolism (HKSPPEM), the Japanese Society for Bone and Mineral Research (JSBMR), the Japan Endocrine Society (JES), the Japanese Society for Pediatric Endocrinology (JSPE), the Korean Society for Bone and Mineral Research (KSBMR), the Korean Endocrine Society (KES), the Korean Society of Pediatric Endocrinology (KSPE), the Malaysian Endocrine and Metabolic Society (MEMS), the Taiwan Paediatric Association, and Taiwan Precision Children's Health Association, for reviewing and endorsing the consensus recommendations. We also acknowledge the participation and valuable contributions of the expert voting group in refining the consensus statements via the Delphi voting. The expert members of the voting group from the UK and APAC regions were Laurent M., UZ Leuven, Leuven, Belgium; Haffner D., Hannover Medical School, Germany; Brandi ML., University of Florence Medical School, Italy; Simm P., Royal Children's Hospital Melbourne, Australia; Wheeler B., University of Otago, New Zealand; Girgis C., University of Sydney and Westmead Hospital, Australia; Loke KY, National University Hospital, Singapore; Yau HC., Prince of Wales Hospital, Hong Kong; Cheung E., United Christian Hospital, Hong Kong; Fukumoto S., Fujii Memorial Institute of Medical Sciences, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan; Hasegawa Y., Division of Endocrinology and Metabolism, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan; Cheong HI., Hallym University Sacred Heart Hospital, Korea; Choi JH., Asan Medical Center, University of Ulsan College of Medicine, Korea; Yoo EG., CHA Bundang Medical Center, Korea; Zhang Z., Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai, China; Liang Y., Tongji Hospital, China; Chen Y., Nanjing Children's Hospital, China; Paul T., Christian Medical College, India; Tung YC., National Taiwan University Hospital, National Taiwan University, Taiwan; Anuar Zaini A., University Malaya, Kuala Lumpur, Malaysia; Soesanti F., Brawijaya Clinic, Jakarta, Indonesia; Huynh Thi Vu Q., University of Medicine and Pharmacy, Ho Chi Minh city, Vietnam; and Phatarakijirund V., Phramongkutklao College of Medicine, Thailand. Additionally, we acknowledge the support from Kyowa Kirin in organizing the advisory board and funding the editorial support from MIMS Pte. Ltd. We thank Sirisha Madhu of MIMS Pte. Ltd. for the conceptualization and implementation of the Delphi method and Tristan Marvin Uy and Sirisha Madhu for providing editorial support for the manuscript.

7. Funding information

Kyowa Kirin provided funding for organizing the advisory board and editorial services from MIMS Pte. Ltd. Kyowa Kirin was not involved in the development, review, or editing of the

manuscript. The content for the manuscript was developed, reviewed, and approved solely by the authors, per the authorship contribution statement.

8. Author contributions

Munns CF, Yoo HW, Jalaludin MY, Vasanwala RF, Chandran M, Rhee Y, But WM, Kong AP, Su PH, Numbenjapon N, Namba N, Imanishi Y, Clifton-Bligh R, Luo X, Xia W: Conceptualization, Methodology, Validation, Data curation, Writing – original draft, Writing – review and editing, Visualization. Munns CF, Xia W: Supervision, Project administration.

9. Conflicts of interest

C.F.M. is a consultant for Kyowa Kirin and has received speaker fees, and research support from Kyowa Kirin. H.W.Y., and M.Y.J. have received honoraria from Kyowa Kirin for speaking engagements. M.C. has received honoraria from Kyowa Kirin for speaking and chairing engagements. R.F.V., W.M.B., and P.H.S. have received speaker and advisor fee from Kyowa Kirin. Y.R. is an investigator in an ongoing, observational study conducted by Kyowa Kirin, and has received honoraria and research fund from Amgen. A.P.K. has received honorarium for consultancy and speaking engagements from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Eli-Lilly, Kyowa Kirin, Merck Serono, Nestle, Novo-Nordisk, Pfizer and Sanofi. N.N. has received speaker and advisor fees from Kyowa Kirin and is an investigator in an ongoing, observational study conducted by Kyowa Kirin. X.L. has no conflicts of interest to declare. Y.I., R.C.B., and W.X. have received research grants and consulting fees from Kyowa Kirin.

10. References

1. Liu S, Guo R, Quarles LD. Cloning and characterization of the proximal murine Phex promoter. *Endocrinology*. 2001;142(9):3987-95.
2. Onishi T, Okawa R, Ogawa T, Shintani S, Ooshima T. Phex mutation causes the reduction of npt2b mRNA in teeth. *J Dent Res*. 2007;86(2):158-62.
3. Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD. Pathogenic role of Fgf23 in Hyp mice. *Am J Physiol Endocrinol Metab*. 2006;291(1):E38-49. Epub 20060131.
4. Carpenter TO, Insogna KL, Zhang JH, Ellis B, Nieman S, Simpson C, et al. Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status. *J Clin Endocrinol Metab*. 2010;95(11):E352-7. Epub 20100804.
5. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. *J Bone Miner Res*. 2004;19(3):429-35. Epub 20031229.
6. Barros NM, Hoac B, Neves RL, Addison WN, Assis DM, Murshed M, et al. Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X-linked hypophosphatemia. *J Bone Miner Res*. 2013;28(3):688-99.

7. Francis F, Hennig S, Korn B, Reinhardt R, de Jong P, Poustka A, et al. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. *Nature Genetics*. 1995;11(2):130-6.
8. Hawley S, Shaw NJ, Delmestri A, Prieto-Alhambra D, Cooper C, Pinedo-Villanueva R, et al. Prevalence and Mortality of Individuals With X-Linked Hypophosphatemia: A United Kingdom Real-World Data Analysis. *J Clin Endocrinol Metab*. 2020;105(3):e871-8.
9. Rafaelsen S, Johansson S, Ræder H, Bjerknes R. Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications. *Eur J Endocrinol*. 2016;174(2):125-36. Epub 20151105.
10. Beck-Nielsen SS, Brock-Jacobsen B, Gram J, Brixen K, Jensen TK. Incidence and prevalence of nutritional and hereditary rickets in southern Denmark. *Eur J Endocrinol*. 2009;160(3):491-7. Epub 20081218.
11. Endo I, Fukumoto S, Ozono K, Namba N, Inoue D, Okazaki R, et al. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. *Endocr J*. 2015;62(9):811-6. Epub 20150701.
12. Haffner D, Emma F, Eastwood DM, Duplan MB, Bacchetta J, Schnabel D, et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. *Nat Rev Nephrol*. 2019;15(7):435-55.
13. Laurent MR, De Schepper J, Trouet D, Godefroid N, Boros E, Heinrichs C, et al. Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium. *Front Endocrinol (Lausanne)*. 2021;12:641543. Epub 20210319.
14. Seefried L, Smyth M, Keen R, Harvengt P. Burden of disease associated with X-linked hypophosphataemia in adults: a systematic literature review. *Osteoporos Int*. 2021;32(1):7-22. Epub 20200724.
15. Ito N, Kang HG, Nishida Y, Evins A, Skrinar A, Cheong HI. Burden of disease of X-linked hypophosphatemia in Japanese and Korean patients: a cross-sectional survey. *Endocr J*. 2022;69(4):373-83. Epub 20211102.
16. Skrinar A, Dvorak-Ewell M, Evins A, Macica C, Linglart A, Imel EA, et al. The Lifelong Impact of X-Linked Hypophosphatemia: Results From a Burden of Disease Survey. *J Endocr Soc*. 2019;3(7):1321-34. Epub 20190507.
17. Hawley S, Shaw NJ, Delmestri A, Prieto-Alhambra D, Cooper C, Pinedo-Villanueva R, et al. Higher prevalence of non-skeletal comorbidity related to X-linked hypophosphataemia: a UK parallel cohort study using CPRD. *Rheumatology (Oxford)*. 2021;60(9):4055-62.
18. Ferizović N, Marshall J, Williams AE, Mughal MZ, Shaw N, Mak C, et al. Exploring the Burden of X-Linked Hypophosphataemia: An Opportunistic Qualitative Study of Patient Statements Generated During a Technology Appraisal. *Adv Ther*. 2020;37(2):770-84. Epub 20191221.
19. Al Juraibah F, Al Amiri E, Al Dubayee M, Al Jubeh J, Al Kandari H, Al Sagheir A, et al. Diagnosis and management of X-linked hypophosphatemia in children and adolescent in the Gulf Cooperation Council countries. *Arch Osteoporos*. 2021;16(1):52. Epub 20210304.

20. Dahir K, Dhaliwal R, Simmons J, Imel EA, Gottesman GS, Mahan JD, et al. Health Care Transition From Pediatric- to Adult-Focused Care in X-linked Hypophosphatemia: Expert Consensus. *J Clin Endocrinol Metab.* 2022;107(3):599-613.
21. Sandy JL, Simm PJ, Biggin A, Rodda CP, Wall CL, Siafarikas A, et al. Clinical practice guidelines for paediatric X-linked hypophosphataemia in the era of burosumab. *J Paediatr Child Health.* 2022;58(5):762-8. Epub 20220415.
22. González-Lamuño D, Lorente Rodríguez A, Luis Yanes MI, Marín-Del Barrio S, Martínez Díaz-Guerra G, Peris P. Clinical practice recommendations for the diagnosis and treatment of X-linked hypophosphatemia: A consensus based on the ADAPTE method. *Med Clin (Barc).* 2022;159(3):152.e1-e12. Epub 20211223.
23. Trombetti A, Al-Daghri N, Brandi ML, Cannata-Andía JB, Cavalier E, Chandran M, et al. Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia. *Nat Rev Endocrinol.* 2022;18(6):366-84. Epub 20220428.
24. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. *J Clin Epidemiol.* 2011;64(4):401-6. Epub 20110105.
25. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, et al. Going from evidence to recommendations. *BMJ.* 2008;336(7652):1049-51.
26. Aguayo-Albasini JL, Flores-Pastor B, Soria-Aledo V. GRADE system: classification of quality of evidence and strength of recommendation. *Cir Esp.* 2014;92(2):82-8. Epub 20131220.
27. GRADE Handbook. 2013. Accessed Aug 22, 2022. Available at: <https://gdt.gradepro.org/app/handbook/handbook.html#h.wsfvfhuxv4r>
28. De Meyer D, Kottner J, Beele H, Schmitt J, Lange T, Van Hecke A, et al. Delphi procedure in core outcome set development: rating scale and consensus criteria determined outcome selection. *J Clin Epidemiol.* 2019;111:23-31. Epub 20190325.
29. Lin X, Zhu Y, Luo J, Huang J. Genetic analysis of three families with X-linked dominant hypophosphatemic rickets. *J Pediatr Endocrinol Metab.* 2018;31(7):789-97.
30. Yue H, Yu JB, He JW, Zhang Z, Fu WZ, Zhang H, et al. Identification of two novel mutations in the PHEX gene in Chinese patients with hypophosphatemic rickets/osteomalacia. *PLoS One.* 2014;9(5):e97830. Epub 20140516.
31. Kang QL, Xu J, Zhang Z, He JW, Lu LS, Fu WZ, et al. Three novel PHEX gene mutations in four Chinese families with X-linked dominant hypophosphatemic rickets. *Biochem Biophys Res Commun.* 2012;423(4):793-8. Epub 20120616.
32. Zhang C, Zhao Z, Sun Y, Xu L, JiaJue R, Cui L, et al. Clinical and genetic analysis in a large Chinese cohort of patients with X-linked hypophosphatemia. *Bone.* 2019;121:212-20. Epub 20190123.
33. Lin X, Li S, Zhang Z, Yue H. Clinical and Genetic Characteristics of 153 Chinese Patients With X-Linked Hypophosphatemia. *Front Cell Dev Biol.* 2021;9:617738. Epub 20210601.
34. Park PG, Lim SH, Lee H, Ahn YH, Cheong HI, Kang HG. Genotype and Phenotype Analysis in X-Linked Hypophosphatemia. *Front Pediatr.* 2021;9:699767. Epub 20210809.
35. Rodríguez-Rubio E, Gil-Peña H, Chocron S, Madariaga L, de la Cerda-Ojeda F, Fernández-Fernández M, et al. Phenotypic characterization of X-linked

- hypophosphatemia in pediatric Spanish population. *Orphanet J Rare Dis*. 2021;16(1):104. Epub 20210227.
36. Marin A, Morales P, Jiménez M, Borja E, Ivanovic-Zuvic D, Collins MT, et al. Characterization of Oral Health Status in Chilean Patients with X-Linked Hypophosphatemia. *Calcif Tissue Int*. 2021;109(2):132-8. Epub 20210410.
 37. Jiménez M, Ivanovic-Zuvic D, Loureiro C, Carvajal CA, Cavada G, Schneider P, et al. Clinical and molecular characterization of Chilean patients with X-linked hypophosphatemia. *Osteoporos Int*. 2021;32(9):1825-36. Epub 20210305.
 38. Baroncelli GI, Zampollo E, Manca M, Toschi B, Bertelloni S, Michelucci A, et al. Pulp chamber features, prevalence of abscesses, disease severity, and PHEX mutation in X-linked hypophosphatemic rickets. *J Bone Miner Metab*. 2021;39(2):212-23. Epub 20200808.
 39. Alikasifoglu A, Unsal Y, Gonc EN, Ozon ZA, Kandemir N, Alikasifoglu M. Long-term effect of conventional phosphate and calcitriol treatment on metabolic recovery and catch-up growth in children with PHEX mutation. *J Pediatr Endocrinol Metab*. 2021;34(12):1573-84. Epub 20210916.
 40. Zheng B, Wang C, Chen Q, Che R, Sha Y, Zhao F, et al. Functional Characterization of PHEX Gene Variants in Children With X-Linked Hypophosphatemic Rickets Shows No Evidence of Genotype-Phenotype Correlation. *J Bone Miner Res*. 2020;35(9):1718-25. Epub 20200512.
 41. Lin Y, Xu J, Li X, Sheng H, Su L, Wu M, et al. Novel variants and uncommon cases among southern Chinese children with X-linked hypophosphatemia. *J Endocrinol Invest*. 2020;43(11):1577-90. Epub 20200406.
 42. Acar S, BinEssa HA, Demir K, Al-Rijjal RA, Zou M, Çatli G, et al. Clinical and genetic characteristics of 15 families with hereditary hypophosphatemia: Novel Mutations in PHEX and SLC34A3. *PLoS One*. 2018;13(3):e0193388. Epub 20180305.
 43. Uday S, Shaw NJ, Mughal MZ, Randell T, Högl W, Santos R, et al. Monitoring response to conventional treatment in children with XLH: Value of ALP and Rickets Severity Score (RSS) in a real world setting. *Bone*. 2021;151:116025. Epub 20210528.
 44. Lecoq AL, Chaumet-Riffaud P, Blanchard A, Dupeux M, Rothenbuhler A, Lambert B, et al. Hyperparathyroidism in Patients With X-Linked Hypophosphatemia. *J Bone Miner Res*. 2020;35(7):1263-73. Epub 20200327.
 45. Meyerhoff N, Haffner D, Staude H, Wühl E, Marx M, Beetz R, et al. Effects of growth hormone treatment on adult height in severely short children with X-linked hypophosphatemic rickets. *Pediatr Nephrol*. 2018;33(3):447-56. Epub 20171020.
 46. Chin YA, Zhao Y, Tay G, Sim W, Chow CY, Chandran M. Delayed Diagnosis, Difficult Decisions: Novel Gene Deletion Causing X-Linked Hypophosphatemia in a Middle-Aged Man with Achondroplastic Features and Tertiary Hyperparathyroidism. *Case Rep Endocrinol*. 2021;2021:9944552. Epub 20210415.
 47. Quinlan C, Guegan K, Offiah A, Neill RO, Hiorns MP, Ellard S, et al. Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment. *Pediatr Nephrol*. 2012;27(4):581-8. Epub 20111120.
 48. Padidela R, Whyte MP, Glorieux FH, Munns CF, Ward LM, Nilsson O, et al. Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia. *Calcif Tissue Int*. 2021;108(5):622-33. Epub 20210123.

49. Mao M, Carpenter TO, Whyte MP, Skrinar A, Chen CY, San Martin J, et al. Growth Curves for Children with X-linked Hypophosphatemia. *J Clin Endocrinol Metab*. 2020;105(10):3243-9.
50. Insogna KL, Briot K, Imel EA, Kamenický P, Ruppe MD, Portale AA, et al. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. *J Bone Miner Res*. 2018;33(8):1383-93. Epub 20180626.
51. Portale AA, Carpenter TO, Brandi ML, Briot K, Cheong HI, Cohen-Solal M, et al. Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period. *Calcif Tissue Int*. 2019;105(3):271-84. Epub 20190604.
52. Beck-Nielsen SS, Brusgaard K, Rasmussen LM, Brixen K, Brock-Jacobsen B, Poulsen MR, et al. Phenotype presentation of hypophosphatemic rickets in adults. *Calcif Tissue Int*. 2010;87(2):108-19. Epub 20100604.
53. Emma F, Cappa M, Antoniazzi F, Bianchi ML, Chiodini I, Eller Vainicher C, et al. X-linked hypophosphatemic rickets: an Italian experts' opinion survey. *Ital J Pediatr*. 2019;45(1):67. Epub 20190531.
54. Al Kaissi A, Farr S, Ganger R, Klaushofer K, Grill F. Windswept lower limb deformities in patients with hypophosphataemic rickets. *Swiss Med Wkly*. 2013;143:w13904. Epub 20131206.
55. Constantacos C, Hunter JD, Walsh ET, South AM. Rare PHEX variant with insidious presentation leads to a delayed diagnosis of X-linked hypophosphatemia. *BMJ Case Rep*. 2021;14(5). Epub 20210519.
56. Gao Y, Wang ZM, Li XL. Analysis of 2 novel mutations of PHEX gene inducing X-linked dominant hypophosphatemia rickets in 2 families: Two case reports. *Medicine (Baltimore)*. 2018;97(31):e11453.
57. Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. *Lancet*. 2019;393(10189):2416-27. Epub 20190516.
58. Carpenter TO, Whyte MP, Imel EA, Boot AM, Höglér W, Linglart A, et al. Burosumab Therapy in Children with X-Linked Hypophosphatemia. *N Engl J Med*. 2018;378(21):1987-98.
59. Insogna KL, Rauch F, Kamenický P, Ito N, Kubota T, Nakamura A, et al. Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X-Linked Hypophosphatemia: A Phase 3, Single-Arm, International Trial. *J Bone Miner Res*. 2019;34(12):2183-91. Epub 20191001.
60. Li SS, Gu JM, Yu WJ, He JW, Fu WZ, Zhang ZL. Seven novel and six de novo PHEX gene mutations in patients with hypophosphatemic rickets. *Int J Mol Med*. 2016;38(6):1703-14. Epub 20161107.
61. Li W, Tan L, Li X, Zhang X, Wu X, Chen H, et al. Identification of a p.Trp403* nonsense variant in PHEX causing X-linked hypophosphatemia by inhibiting p38 MAPK signaling. *Hum Mutat*. 2019;40(7):879-85. Epub 20190328.
62. Mornet E. Hypophosphatasia. *Orphanet J Rare Dis*. 2007;2:40. Epub 20071004.

63. Whyte MP, Carpenter TO, Gottesman GS, Mao M, Skrinar A, San Martin J, et al. Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. *Lancet Diabetes Endocrinol.* 2019;7(3):189-99. Epub 20190109.
64. Lee KS, Lee BL. The first Korean case report with scaphocephaly as the initial sign of X-linked hypophosphatemic rickets. *Childs Nerv Syst.* 2019;35(6):1045-9. Epub 20190106.
65. Vakharia JD, Matlock K, Taylor HO, Backeljauw PF, Topor LS. Craniosynostosis as the Presenting Feature of X-linked Hypophosphatemic Rickets. *Pediatrics.* 2018;141(Suppl 5):S515-s9.
66. Yang L, Yang J, Huang X. PHEX gene mutation in a Chinese family with six cases of X-linked hypophosphatemic rickets. *J Pediatr Endocrinol Metab.* 2013;26(11-12):1179-83.
67. Briot K, Portale AA, Brandi ML, Carpenter TO, Cheong HI, Cohen-Solal M, et al. Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension. *RMD Open.* 2021;7(3).
68. Walton RJ, Bijvoet OL. Nomogram for derivation of renal threshold phosphate concentration. *Lancet.* 1975;2(7929):309-10.
69. Bistarakis L, Voskaki I, Lambadaridis J, Sereti H, Sbyrakakis S. Renal handling of phosphate in the first six months of life. *Arch Dis Child.* 1986;61(7):677-81.
70. Brodehl J, Krause A, Hoyer PF. Assessment of maximal tubular phosphate reabsorption: comparison of direct measurement with the nomogram of Bijvoet. *Pediatr Nephrol.* 1988;2(2):183-9.
71. Shaw NJ, Wheeldon J, Brocklebank JT. Indices of intact serum parathyroid hormone and renal excretion of calcium, phosphate, and magnesium. *Arch Dis Child.* 1990;65(11):1208-11.
72. Harris H. The human alkaline phosphatases: what we know and what we don't know. *Clin Chim Acta.* 1990;186(2):133-50.
73. Sharma U, Pal D, Prasad R. Alkaline phosphatase: an overview. *Indian J Clin Biochem.* 2014;29(3):269-78. Epub 20131126.
74. Fleisher GA, Eickelberg ES, Elveback LR. Alkaline phosphatase activity in the plasma of children and adolescents. *Clin Chem.* 1977;23(3):469-72.
75. Ishihara Y, Ohata Y, Takeyari S, Kitaoka T, Fujiwara M, Nakano Y, et al. Genotype-phenotype analysis, and assessment of the importance of the zinc-binding site in PHEX in Japanese patients with X-linked hypophosphatemic rickets using 3D structure modeling. *Bone.* 2021;153:116135. Epub 20210730.
76. Kinoshita Y, Saito T, Shimizu Y, Hori M, Taguchi M, Igarashi T, et al. Mutational analysis of patients with FGF23-related hypophosphatemic rickets. *Eur J Endocrinol.* 2012;167(2):165-72. Epub 20120510.
77. Steele A, Gonzalez R, Garbalosa JC, Steigbigel K, Grgurich T, Parisi EJ, et al. Osteoarthritis, Osteophytes, and Enthesophytes Affect Biomechanical Function in Adults With X-linked Hypophosphatemia. *J Clin Endocrinol Metab.* 2020;105(4):e1798-814.

78. Mindler GT, Kranzl A, Stauffer A, Haeusler G, Ganger R, Raimann A. Disease-specific gait deviations in pediatric patients with X-linked hypophosphatemia. *Gait Posture*. 2020;81:78-84. Epub 20200712.
79. Che H, Roux C, Etcheto A, Rothenbuhler A, Kamenicky P, Linglart A, et al. Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms. *Eur J Endocrinol*. 2016;174(3):325-33.
80. Lo SH, Lachmann R, Williams A, Piglowska N, Lloyd AJ. Exploring the burden of X-linked hypophosphatemia: a European multi-country qualitative study. *Qual Life Res*. 2020;29(7):1883-93. Epub 20200311.
81. Biosse Duplan M, Coyac BR, Bardet C, Zadikian C, Rothenbuhler A, Kamenicky P, et al. Phosphate and Vitamin D Prevent Periodontitis in X-Linked Hypophosphatemia. *J Dent Res*. 2017;96(4):388-95. Epub 20161113.
82. Connor J, Olear EA, Insogna KL, Katz L, Baker S, Kaur R, et al. Conventional Therapy in Adults With X-Linked Hypophosphatemia: Effects on Enthesopathy and Dental Disease. *J Clin Endocrinol Metab*. 2015;100(10):3625-32. Epub 20150715.
83. Cheung M, Roschger P, Klaushofer K, Veilleux LN, Roughley P, Glorieux FH, et al. Cortical and trabecular bone density in X-linked hypophosphatemic rickets. *J Clin Endocrinol Metab*. 2013;98(5):E954-61. Epub 20130326.
84. Jin C, Zhang C, Ni X, Zhao Z, Xu L, Wu B, et al. The efficacy and safety of different doses of calcitriol combined with neutral phosphate in X-linked hypophosphatemia: a prospective study. *Osteoporos Int*. 2022;33(6):1385-95. Epub 20220127.
85. Sullivan W, Carpenter T, Glorieux F, Travers R, Insogna K. A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets. *J Clin Endocrinol Metab*. 1992;75(3):879-85.
86. Linglart A, Biosse-Duplan M, Briot K, Chaussain C, Esterle L, Guillaume-Czitrom S, et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. *Endocr Connect*. 2014;3(1):R13-30. Epub 20140314.
87. Alon US, Monzavi R, Lilien M, Rasoulpour M, Geffner ME, Yadin O. Hypertension in hypophosphatemic rickets--role of secondary hyperparathyroidism. *Pediatr Nephrol*. 2003;18(2):155-8. Epub 20030118.
88. Yanes MIL, Diaz-Curiel M, Peris P, Vicente C, Marin S, Ramon-Krauel M, et al. Health-related quality of life of X-linked hypophosphatemia in Spain. *Orphanet J Rare Dis*. 2022;17(1):298. Epub 20220729.
89. European Medicines Agency. Crysvida: EPAR Product Information. 2018 (Updated Oct 12, 2021). Accessed Jul 22, 2022. Available at: https://www.ema.europa.eu/en/documents/product-information/crysvida-epar-product-information_en.pdf
90. Food and Drug Administration (US). Drug Approval Package: CRYSVITA (burosumab-twza). 2018. Accessed Jul 22, 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761068Orig1s000Lbl.pdf
91. Ward LM, Glorieux FH, Whyte MP, Munns CF, Portale AA, Högl W, et al. Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia. *J Clin Endocrinol Metab*. 2022;107(8):e3241-e53.
92. Carpenter TO, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Wooddell MM, et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. *J Clin Invest*. 2014;124(4):1587-97. Epub 20140224.

93. Harada D, Ueyama K, Oriyama K, Ishiura Y, Kashiwagi H, Yamada H, et al. Switching from conventional therapy to burosumab injection has the potential to prevent nephrocalcinosis in patients with X-linked hypophosphatemic rickets. *J Pediatr Endocrinol Metab.* 2021;34(6):791-8. Epub 20210412.
94. Martín Ramos S, Gil-Calvo M, Roldán V, Castellano Martínez A, Santos F. Positive Response to One-Year Treatment With Burosumab in Pediatric Patients With X-Linked Hypophosphatemia. *Front Pediatr.* 2020;8:48. Epub 20200218.
95. Imel EA, Zhang X, Ruppe MD, Weber TJ, Klausner MA, Ito T, et al. Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. *J Clin Endocrinol Metab.* 2015;100(7):2565-73. Epub 20150428.
96. Linglart A, Imel EA, Whyte MP, Portale AA, Höglér W, Boot AM, et al. Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia. *J Clin Endocrinol Metab.* 2022;107(3):813-24.
97. Namba N, Kubota T, Muroya K, Tanaka H, Kanematsu M, Kojima M, et al. Safety and Efficacy of Burosumab in Pediatric Patients With X-Linked Hypophosphatemia: A Phase 3/4 Open-Label Trial. *J Endocr Soc.* 2022;6(5):bvac021. Epub 20220211.
98. Department of Health and Aged Care (AU). Pharmaceutical Benefits Advisory Committee (PBAC) Meeting Outcomes. 2022 (updated Aug 19, 2022). Accessed August 30, 2022. Available at: <https://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/pbac-outcomes>
99. Smith S, Remington T. Recombinant growth hormone therapy for X-linked hypophosphatemia in children. *Cochrane Database Syst Rev.* 2021;10(10):Cd004447. Epub 20211007.
100. André J, Zhukouskaya VV, Lambert AS, Salles JP, Mignot B, Bardet C, et al. Growth hormone treatment improves final height in children with X-linked hypophosphatemia. *Orphanet J Rare Dis.* 2022;17(1):444. Epub 20221221.
101. Ertl DA, Le Lorier J, Gleiss A, Trabado S, Bensignor C, Audrain C, et al. Growth pattern in children with X-linked hypophosphatemia treated with burosumab and growth hormone. *Orphanet J Rare Dis.* 2022;17(1):412. Epub 20221112.
102. Chesher D, Oddy M, Darbar U, Sayal P, Casey A, Ryan A, et al. Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations. *J Inherit Metab Dis.* 2018;41(5):865-76. Epub 20180219.
103. Kovacs CS. Calcium and Phosphate Metabolism and Related Disorders During Pregnancy and Lactation. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, et al., editors. *Endotext*. South Dartmouth (MA): MDText.com, Inc.; 2000.
104. Brandi ML, Ariceta G, Beck-Nielsen SS, Boot AM, Briot K, de Lucas Collantes C, et al. Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-linked hypophosphataemia: rationale and description. *Ther Adv Chronic Dis.* 2022;13:20406223221117471. Epub 20220905.
105. Hughes M, Macica C, Meriano C, Doyle M. Giving Credence to the Experience of X-Linked Hypophosphatemia in Adulthood: An Interprofessional Mixed-Methods Study. *J Patient Cent Res Rev.* 2020;7(2):176-88. Epub 20200427.
106. Rothenbuhler A, Fadel N, Debza Y, Bacchetta J, Diallo MT, Adamsbaum C, et al. High Incidence of Cranial Synostosis and Chiari I Malformation in Children With X-Linked

- Hypophosphatemic Rickets (XLHR). *J Bone Miner Res.* 2019;34(3):490-6. Epub 20181120.
107. Sass P, Hassan G. Lower extremity abnormalities in children. *Am Fam Physician.* 2003;68(3):461-8.
108. Nakamura Y, Takagi M, Takeda R, Miyai K, Hasegawa Y. Hypertension is a characteristic complication of X-linked hypophosphatemia. *Endocr J.* 2017;64(3):283-9. Epub 20161227.
109. Brotto M, Johnson ML. Endocrine crosstalk between muscle and bone. *Curr Osteoporos Rep.* 2014;12(2):135-41.
110. Ros I, Alvarez L, Guañabens N, Peris P, Monegal A, Vázquez I, et al. Hypophosphatemic osteomalacia: a report of five cases and evaluation of bone markers. *J Bone Miner Metab.* 2005;23(3):266-9.
111. Schmitt CP, Mehls O. The enigma of hyperparathyroidism in hypophosphatemic rickets. *Pediatr Nephrol.* 2004;19(5):473-7. Epub 20040311.
112. Kritmetapak K, Kumar R. Phosphate as a Signaling Molecule. *Calcif Tissue Int.* 2021;108(1):16-31. Epub 20191125.
113. Goodyer PR, Kronick JB, Jequier S, Reade TM, Scriver CR. Nephrocalcinosis and its relationship to treatment of hereditary rickets. *J Pediatr.* 1987;111(5):700-4.
114. US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, et al. Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement. *JAMA.* 2018;319(24):2521-31.
115. Colares Neto GP, Pereira RM, Alvarenga JC, Takayama L, Funari MF, Martin RM. Evaluation of bone mineral density and microarchitectural parameters by DXA and HR-pQCT in 37 children and adults with X-linked hypophosphatemic rickets. *Osteoporos Int.* 2017;28(5):1685-92. Epub 20170213.
116. Beck-Nielsen SS, Brixen K, Gram J, Mølgaard C. High bone mineral apparent density in children with X-linked hypophosphatemia. *Osteoporos Int.* 2013;24(8):2215-21. Epub 20130207.
117. Baroncelli GI, Bertelloni S, Cosci ODCM, Tyutyusheva N, D'Elia S, Peroni D. Management of patients with X-linked hypophosphatemic rickets during Covid-19 pandemic lockdown. *J Pediatr Endocrinol Metab.* 2021;34(7):905-10. Epub 20210423.
118. UNC STARx Program. Version of The TRxANSITION Index™. Accessed Jul 22, 2022. Available at: <https://www.med.unc.edu/transition/transition-tools/starx-questionnaire/versions-of-the-trxansition-indextm/>
119. East Tennessee State University. The TRAQ in Different Languages The languages of the TRAQ and their studies n.d. Accessed Jul 22, 2022. Available at: <https://www.etsu.edu/com/pediatrics/traq/traq.different.languages.php>

Figure legends

Figure 1. Flow diagram for article selection.

Figure 2. Asia-Pacific consensus recommendations on goals of multidisciplinary management of X-linked hypophosphatemia

Figure 3. Asia-Pacific consensus recommendations on timelines and goals for optimized transition of care of XLH.

Figure 4. Asia-Pacific consensus recommendations on roles and responsibilities to ensure optimized transition of care of XLH.

Table 1. Central themes of the 16 consensus statements and summary of agreement ratings from the two rounds of Delphi voting.

Consensus statement	Agreement rating on Delphi 1	Agreement rating on Delphi 2
<i>Theme: Screening and diagnosis</i>		
Statement 1A	84.21%	97.37%
Statement 1B	81.58%	100%
Statement 2A	76.32%	94.74%
Statement 2B	68.42%	94.74%
Statement 3A	76.32%	92.11%
Statement 3B	68.42%	97.37%
<i>Theme: Multidisciplinary management</i>		
Statement 4	92.11%	100%
Statement 5	81.58%	97.37%
Statement 6	94.74%	100%
Statement 7	89.47%	100%
Statement 8	71.05%	100%
Statement 9	68.42%	100%
Statement 10	78.95%	97.37%
Statement 11	92.11%	100%
Statement 12	100%	—
<i>Theme: Transition of care from childhood to adulthood</i>		
Statement 13	89.47%	100%
Statement 14A	97.37%	97.37%
Statement 14B	94.74%	100%
Statement 14C	89.47%	100%
Statement 15	89.47%	97.37%
<i>Theme: Education and training</i>		
Statement 16	97.37%	100%

Table 2. Asia-Pacific consensus recommendations for optimizing the screening and diagnosis of XLH.

Statement 1A	GRADE Evidence Quality: ⊕⊕⊕○ Moderate
Renal phosphate wasting conditions should be suspected and evaluated further in children with decreased growth velocity, short stature, ^a and/or lower limb deformities with radiographic and/or clinical evidence of rickets. ^b Additional red flags may include a history of recurrent clinically significant fragility fractures, abnormal (waddling) gait, impaired gross motor function, bone pain, abnormal head shape with frontal bossing or craniosynostosis, recurrent dental abscess, or a family history of rickets or phosphate wasting disorder.	
Statement 1B	GRADE Evidence Quality: ⊕⊕⊕○ Moderate
Hereditary (or congenital) renal phosphate wasting conditions should be suspected and evaluated further in adults with low serum phosphate levels and short stature, ^a radiographic evidence of early degenerative arthritis, osteoporosis, pseudofractures or enthesopathies, bone pain with a history of lower limb deformities, or history of vitamin D-resistant rickets or corrective osteotomy. Additional red flags may include endodontic abnormalities such as periodontitis, dental abscess, or premature loss of permanent teeth, or a family history of rickets or phosphate wasting disorders.	
Statement 2A	GRADE Evidence Quality: ⊕⊕⊕⊕ High
<p>The ‘essential’ clinical and/or radiological features for a presumptive diagnosis of XLH in children should include the following–</p> <ul style="list-style-type: none"> • Decreased growth velocity^c • Short stature^{a,c} • Progressive lower limb (varus or valgus) deformities often combined with intoeing/out-toeing^c • Clinical and/or radiographic signs of active rickets in the knees and/or wrists that does not heal with ≥3 months of calcium and vitamin D treatment <p>The ‘essential’ biochemical criteria to confirm the diagnosis of XLH in children should include all of the following–</p> <ul style="list-style-type: none"> • Serum phosphate level below the age-related reference range^d • Renal phosphate wasting [assessed by calculating renal tubular reabsorption of phosphate in the fasting state (TmP/GFR and %TRP) based on urinary and serum phosphate and creatinine levels] – other renal reasons for phosphaturia should be excluded by evaluating for glucosuria, proteinuria, aminoaciduria, and excessive urinary excretion of bicarbonate • Persistently elevated ALP levels above the age-related reference range 	
Statement 2B	GRADE Evidence Quality: ⊕⊕⊕⊕ High
<p>The additional criteria to support or further confirm the diagnosis of XLH in children may include –</p> <ul style="list-style-type: none"> • Clinical: Abnormal (waddling) gait, abnormal head shape; frontal bossing; recurrent dental abscess; large head circumference; bone pain • Imaging: Widened, cupped, flared and frayed metaphyses or costochondral junctions (rachitic rosary); Harrison’s groove; craniosynostosis (CT/MRI); and/or Chiari type 1 malformation (CT/MRI) • Biochemical: Normal serum calcium levels, normal or mildly elevated PTH levels, normal 25-hydroxy vitamin D, low or inappropriately normal 1,25-dihydroxy vitamin D, and/or elevated or inappropriately normal FGF23 	

<ul style="list-style-type: none"> Genetic: A positive family history of XLH (X-linked dominant inheritance) and/or detection of pathogenic <i>PHEX</i> gene mutations – genetic criteria will help further confirm the diagnosis of XLH. 	
Statement 3A	Overall GRADE Evidence Quality: ⊕⊕⊕⊕ High
<p>The ‘essential’ criteria to confirm the diagnosis of XLH in adults should include the following biochemical features–</p> <ul style="list-style-type: none"> Serum phosphate level below the laboratory reference range^d Renal phosphate wasting [assessed by calculating renal tubular reabsorption of phosphate in the fasting state (TmP/GFR and %TRP) based on urinary and serum phosphate and creatinine levels] – other renal reasons for phosphaturia should be excluded by evaluating for glucosuria, proteinuria, aminoaciduria, and excessive urinary excretion of bicarbonate. <p>Additional clinical & imaging features that may help further confirm the diagnosis include–</p> <ul style="list-style-type: none"> Short stature^a Presence or history of pseudofractures, and/or lower limb deformities 	
Statement 3B	GRADE Evidence Quality: ⊕⊕⊕⊕ High
<p>The ‘additional’ criteria to support or further confirm the diagnosis of XLH in adults may include –</p> <ul style="list-style-type: none"> Clinical: Bone pain, stiffness, reduced functional capacity (e.g., as assessed by six-minute walk test) and/or recurrent dental abnormalities such as periodontitis or dental abscess Imaging: Radiological signs of osteomalacia, early osteoarthritis of the spine, hip, or knees and/or enthesopathies Biochemical: Normal serum calcium levels, normal 25-hydroxy vitamin D and inappropriately normal or low 1,25-dihydroxy vitamin D, normal or elevated ALP levels, normal or elevated PTH levels, and/or elevated or inappropriately normal FGF23 Genetic: A positive family history of XLH (X-linked dominant inheritance) and/or detection of pathogenic <i>PHEX</i> gene mutations – genetic criteria will help further confirm the diagnosis of XLH. 	

^aDisproportionate short stature in severe cases (impaired limb growth with preserved trunk growth)

^bRadiographic and/or clinical rickets that does not heal even after 3 months of vitamin D and calcium supplementation - for APAC regions with moderate-to-high prevalence of nutritional rickets.

^cPrimarily in children who have started to walk (>1–1.5 years of age)

^dIf clinical suspicion exists and serum phosphate levels are normal, 'fasting' serum phosphate test should be conducted.

ALP, alkaline phosphatase; CT, computed tomography; FGF23, fibroblast growth factor 23; GRADE, Grading of Recommendations, Assessment, Development and Evaluations; MRI, magnetic resonance imaging; PHEX, Phosphate Endopeptidase Homolog X-linked; PTH, parathyroid hormone; TmP/GFR, tubular maximum reabsorption of phosphate per glomerular filtration rate; TRP, tubular reabsorption of phosphate; XLH, X-linked hypophosphatemia

Table 3. Asia-Pacific consensus recommendations for the pharmacologic treatment of XLH.

Statement 5A	GRADE Evidence Quality: ⊕⊕⊕⊕ High
Children and symptomatic adults with XLH should be treated with a combination of oral phosphate and active vitamin D (calcitriol or alfacalcidol) according to international or national guidelines. The benefits and side-effects of conventional oral phosphate plus active vitamin D should be discussed with the patient prior to initiating treatment.	
Statement 5B	GRADE Evidence Quality: ⊕⊕⊕⊕ High
Children and adults with XLH on treatment with conventional active vitamin D and oral phosphate should be monitored closely for prevention and early management of associated complications such as gastrointestinal discomfort, hyperparathyroidism, hypercalciuria, hypercalcemia, renal insufficiency or nephrocalcinosis/nephrolithiasis.	
Statement 5C	GRADE Evidence Quality: Expert opinion
Accessibility to appropriate optimal forms of phosphate salts and/or active vitamin D is a major issue in several APAC regions. All APAC countries should have access to appropriate forms of oral phosphate (or pharmaceutical grade phosphate) and active vitamin D for early and optimized management of XLH and prevention of XLH-associated complications.	
Statement 5D	GRADE Evidence Quality: ⊕⊕⊕⊕ High
Treatment with burosumab should be initiated, if available, in children aged ≥1 year, adolescents, and adults with XLH, and monitored according to indications and guidance provided in the product prescribing information.	
Statement 5E	Evidence Quality: Expert opinion
Accessibility to burosumab should be improved in APAC settings to enable optimization of XLH management, improvement in functional and patient-reported outcomes and quality of life, and prevention of XLH-associated complications, including fractures.	
Statement 6	Evidence Quality: Expert Opinion
Pregnant and lactating women with XLH may be treated with active vitamin D in combination with oral phosphate supplements, if needed. However, they should be monitored more frequently (at least once every 3 months) for complications. Burosumab is currently not recommended during pregnancy. It is unknown whether burosumab or its metabolites are excreted in human milk.	

APAC, Asia-Pacific; GRADE, Grading of Recommendations, Assessment, Development and Evaluations; XLH, X-linked hypophosphatemia

Table 4. Asia-Pacific consensus recommendations for multidisciplinary referral of patients with XLH.

Statement 7	GRADE Evidence Quality
We recommend that, if resources are available, a child with suspected or confirmed XLH should be referred to and followed-up by a multidisciplinary team comprising of:	
A. A physician with special interest in XLH, often a pediatric endocrinologist, but in some settings, a pediatric nephrologist or a general pediatrician – for the medical treatment of metabolic bone disease and other complications (e.g., pain) associated with XLH and its treatment	⊕⊕⊕⊕ High
B. An orthopedic surgeon for timely surgical correction of skeletal deformities	⊕⊕⊕⊕ High
C. A dentist or endodontist for regular screening, prevention and timely treatment of dental conditions such as periodontitis or dental abscess	⊕⊕⊕⊕ High
D. A neurosurgeon or craniofacial surgeon, in case of complications such as craniosynostosis, syringomyelia or Chiari I malformation or abnormal clinical findings such as elevated intracranial pressure or headache	⊕⊕⊕⊕ High
E. A physiotherapist and occupational therapist for improvement in muscle strength, stiffness, pain, mobility, gait, and optimal school participation, especially after orthopedic surgery	Expert opinion
F. An otolaryngologist or audiologist for regular screening of hearing impairment	⊕⊕⊕○ Moderate
Optimal multidisciplinary care of children with XLH may also include referral to the following specialties based on the available resources –	
G. A clinical psychologist (or a trained social worker in some APAC settings) for counselling and improvement in mental health and stigma associated with XLH	⊕⊕⊕○ Moderate
H. A dietician or nutritionist for counselling on healthy dietary choices	Expert opinion
I. Geneticist or genetic counsellor at the time of diagnosis of XLH	Expert opinion
Statement 8	GRADE Evidence Quality
We recommend that, if resources are available, an adult diagnosed with XLH should be referred to and followed-up by a multidisciplinary team comprising of:	
A. A physician with experience or special interest in XLH, often adult endocrinologist, but in some settings, nephrologist, or general internist (internal medicine specialist) – for the medical treatment of metabolic bone disease and other complications (e.g., pain) associated with XLH and its treatment	⊕⊕⊕⊕ High
B. A physiotherapist, occupational therapist, physiatrist, or rehabilitation specialist for improvement in muscle strength, stiffness, pain, mobility, and workforce participation, especially after orthopedic surgery	⊕⊕⊕⊕ High

C. A dentist or endodontist for screening, prevention, and timely treatment of dental conditions such as periodontitis or dental abscess	⊕⊕⊕⊕ High
D. An orthopedic surgeon or rheumatologist, in case of any skeletal deformities or orthopedic conditions such as osteoarthritis or enthesopathies for timely correction and management of the conditions	⊕⊕⊕⊕ High
E. Geneticist or genetic counsellor, when planning for family	⊕⊕⊕○ Moderate
Optimal multidisciplinary care of adults with XLH may also include referral to the following specialties, based on the clinical symptoms, available resources and individual needs –	
F. A neurosurgeon in case of neurologic complications such as Chiari I malformations, abnormal clinical findings such as elevated intracranial pressure or headache, or spinal stenosis	⊕⊕⊕○ Moderate
G. An audiologist or otolaryngologist for screening, early detection, and treatment of hearing impairment	⊕⊕⊕○ Moderate
H. A clinical psychologist for counselling and improvement in mental health and stigma associated with XLH	⊕⊕⊕○ Moderate
I. A gynecologist and obstetrician in case of women with XLH	Expert Opinion
J. A dietician or nutritionist for counselling on healthy dietary choices	Expert Opinion

APAC, Asia-Pacific; GRADE, Grading of Recommendations, Assessment, Development and Evaluations; XLH, X-linked hypophosphatemia

Table 5. Asia-Pacific consensus recommendations for the follow-up monitoring of XLH in children.

Monitoring assessment		GRADE evidence rating	Assessment frequency (Expert Opinion)
Statement 9: The recommended follow-up monitoring assessments, and their frequency in children with XLH to ensure optimized multidisciplinary treatment and care include:			
Clinical	Height/length, weight, BMI, head circumference, growth velocity, blood pressure	⊕⊕⊕⊕ High	1-3 months for at least 1 year after XLH diagnosis and treatment initiation, followed by 3-monthly, thereafter. Blood pressure assessment should be initiated once the child is compliant with testing.
	Limb pain (bone, muscle joint), headache		
	Intermalleolar distance, intercondylar distance, skull shape		
Biochemical	Serum calcium, serum or plasma phosphate, creatinine, ALP	⊕⊕⊕⊕ High	1-3 months for at least 1 year after XLH diagnosis and treatment initiation, followed by 3-monthly, thereafter (creatinine and blood urea nitrogen to be monitored as needed, e.g., in case of nephrocalcinosis)
	PTH	⊕⊕⊕⊕ High	
	Urine calcium: creatinine ratio	⊕⊕⊕⊕ High	Annually
	25-hydroxy vitamin D	⊕⊕⊕⊕ High	Annually
	1,25-dihydroxy vitamin D	⊕⊕⊕⊕ High	Annually, only in patients on burosumab, based on availability of resources
Radiological	Bone age X-ray	⊕⊕⊕⊕ High	Once in every 1–2 years, or as clinically indicated
	Other X-ray imaging	⊕⊕⊕⊕ High	As clinically indicated
	Renal ultrasound	⊕⊕⊕⊕ High	Annually
Orthopedic		⊕⊕⊕⊕ High	Children with limb deformities, unexplained gait abnormalities or persistent bone pain
Craniofacial		⊕⊕⊕○ Moderate	

Neurosurgical		⊕⊕⊕○ Moderate	Referral to neurosurgeon if resources are available – (1) For screening of complications such as craniosynostosis, syringomyelia or Chiari I malformation; and (2) For treatment and subsequent monitoring in case of abnormal clinical findings such as elevated intracranial pressure, headache, etc.
Dental		⊕⊕⊕⊕ High	Twice yearly
Hearing		⊕⊕○○ Low	Assessment should be initiated at 8 years of age or earlier, as needed. Patients with hearing difficulties should be referred to an otolaryngologist for treatment and subsequent monitoring
Genetic counselling		Expert Opinion	Counselling to parents and caregivers of children diagnosed with XLH at the time of diagnosis or for family planning
Functional	Developmental milestones, school participation	Expert opinion	At every clinic visit
	6MWT, ABC scale, sit-to-stand	⊕⊕⊕⊕ High	Annually, based on availability of resources
Psychosocial (using specific questionnaires)		⊕⊕⊕○ Moderate	Annually, based on availability of resources

ABC, Activity-specific Balance Confidence; 6MWT, 6-minute walk test; ALP, alkaline phosphatase; BMI, body mass index; GRADE, Grading of Recommendations, Assessment, Development and Evaluations; PTH, parathyroid hormone; XLH, X-linked hypophosphatemia

Table 6. Asia-Pacific consensus recommendations for the follow-up monitoring of XLH in adolescents.

Monitoring assessment		GRADE evidence rating	Assessment frequency (Expert opinion)
Statement 10: The recommended follow-up monitoring assessments, and their frequency in adolescents with XLH to ensure optimized multidisciplinary treatment and care include:			
Clinical	Height/length, growth velocity, weight, BMI, blood pressure Limb pain (bone, muscle joint, joint mobility), headache Intermalleolar distance, intercondylar distance	⊕⊕⊕○ Moderate	1-3 months for at least 1 year after XLH diagnosis and treatment initiation, followed by 3-monthly, thereafter.
Biochemical	Serum calcium, serum/plasma phosphate, creatinine, ALP	⊕⊕⊕○ Moderate	Every 3 months
	PTH	⊕⊕○○ Low	
	Urine calcium: creatinine ratio	⊕○○○ Very low	Annually
	25-hydroxy vitamin D	⊕○○○ Very low	Annually
	1,25-dihydroxy vitamin D	⊕○○○ Very low	Annually, only in patients on burosumab based on availability of resources
Radiological	Bone age X-ray	⊕⊕⊕⊕ High	Once every 1–2 years, or as clinically indicated
	Other X-ray imaging	⊕⊕⊕○ Moderate	As clinically indicated
	Renal ultrasound	⊕⊕⊕○ Moderate	Annually
Orthopedic		⊕⊕⊕⊕ High	Adolescents with limb deformities, unexplained gait abnormalities or persistent bone pain
Craniofacial		Expert opinion	Adolescents with relevant abnormal clinical findings suggesting elevated intracranial pressure, headache, etc. should be referred to neurosurgeon for treatment and subsequent monitoring
Neurosurgical		⊕⊕○○ Low	
Dental		⊕⊕⊕⊕ High	Twice yearly

Hearing		⊕○○○ Very low	Adolescents with hearing difficulties should be referred to an otolaryngologist for treatment and subsequent monitoring
Genetic counselling		Expert opinion	During transition to adolescence
Functional	School participation, academic performance	Expert opinion	At every clinic visit
	6MWT, ABC scale, sit-to-stand	⊕⊕○○ Low	Annually, based on availability of resources
Psychosocial (using specific questionnaires)		⊕⊕⊕○ Moderate	Annually, based on availability of resources

ABC, Activity-specific Balance Confidence; 6MWT, 6-minute walk test; ALP, alkaline phosphatase; BMI, body mass index; GRADE, Grading of Recommendations, Assessment, Development and Evaluations; PTH, parathyroid hormone; XLH, X-linked hypophosphatemia

Table 7. Asia-Pacific consensus recommendations for the follow-up monitoring of XLH in adults.

Monitoring assessment		GRADE evidence rating	Assessment frequency (Expert Opinion)
Statement 11: The recommended follow-up monitoring assessments, and their frequency in adults with XLH to ensure optimized multidisciplinary treatment and care include:			
Clinical	Height, weight, BMI, blood pressure Limb pain (bone, muscle joint, joint mobility), headache	⊕⊕⊕⊕ High	Annually or at each follow-up visit
Biochemical	Serum/plasma phosphate	⊕⊕⊕⊕ High	Every 3 months or at each follow-up visit in symptomatic adults and/or adults undergoing treatment
	Serum calcium, serum creatinine, ALP	⊕⊕⊕⊕ High	Annually
	PTH	⊕⊕⊕⊕ High	Annually (every 3 months in patients with elevated PTH)
	25-hydroxy vitamin D	⊕⊕⊕⊕ High	Annually
	1,25-dihydroxy vitamin D	⊕○○○ Very low	Annually, only in patients on burosumab based on availability of resources
Radiological	X-ray imaging	⊕⊕⊕⊕ High	As indicated
	DXA	⊕⊕⊕○ Moderate	As indicated (may be considered only in XLH patients aged >50 years or in post-menopausal women)
	Renal ultrasound	⊕⊕⊕⊕ High	Annually or every 2 years only in patients on conventional or burosumab therapy, or in patients with pre-existing nephrocalcinosis and/or tertiary hyperparathyroidism
Orthopedic		⊕⊕⊕⊕ High	Adults with limb deformities, limb pain or fracture/pseudofractures should be referred to

			orthopedic surgeon for treatment and subsequent monitoring
Craniofacial		⊕⊕○○ Low	Adults with complications such as Chiari I malformations or spinal stenosis or relevant abnormal clinical findings such as elevated intracranial pressure, headache, etc. should be referred to neurosurgeon for treatment and subsequent monitoring
Neurosurgical		⊕⊕⊕○ Moderate	
Dental		⊕⊕⊕⊕ High	Twice yearly
Hearing		⊕⊕○○ Low	Adults with hearing difficulties should be referred to an otolaryngologist for treatment and subsequent monitoring
Genetic counselling		Expert Opinion	For women with XLH planning pregnancy or are pregnant along with their partners, and For women planning pregnancy or are pregnant with their XLH partners
Functional	6MWT, ABC, sit-to-stand, grip strength test	⊕⊕⊕⊕ High	Annually or every 2 years; regular assessment post-surgery, including one scheduled at 12 months
Psychosocial	(using specific questionnaires)	⊕⊕⊕○ Moderate	Annually, based on availability of resources

ABC, Activity-specific Balance Confidence; 6MWT, 6-minute walk test; ALP, alkaline phosphatase; BMI, body mass index; DXA, dual-energy x-ray absorptiometry; GRADE, Grading of Recommendations, Assessment, Development and Evaluations; PTH, parathyroid hormone; XLH, X-linked hypophosphatemia

Table 8. Asia-Pacific consensus recommendations on the role of telemedicine in care for XLH.

Statement 12	GRADE Evidence Quality: ⊕⊕⊕○Moderate
Telemedicine and digital medicine (in APAC settings, where it is legally approved) may help in supporting XLH patients to access care easily (e.g., rural, or remote settings) or when hospital admissions are restricted. However, telemedicine cannot replace face-to-face consultations, especially if physical examination, and diagnostic imaging are required.	

APAC, Asia-Pacific; GRADE, Grading of Recommendations, Assessment, Development and Evaluations; XLH, X-linked hypophosphatemia

Table 9. Asia-Pacific consensus recommendations for the use of transition questionnaires and transition clinics in XLH.

Statement 14B	Evidence Quality: Expert Opinion
Validated transition questionnaires such as the Transition Readiness Assessment Questionnaire (TRAQ) may be considered starting two-years prior to transition, followed by every 1–2 years till transition, to assess the transition readiness of patients and parents/caregivers, in settings where it is feasible to use the validated English version of the questionnaire. Local validated (translated) versions of TRAQ may have to be developed to be used in specific local settings.	
Statement 14C	Evidence Quality: Expert Opinion
Transition clinics are important for optimizing the transition of care of XLH patients from childhood to adulthood. If resources are available, a typical ‘bone and metabolic disorder’ or ‘XLH’ transition clinic may comprise of a pediatric treating specialist, an adult treating specialist, a nurse or case manager, patients with XLH and parents or caregivers. The first transition clinic may be conducted in a familiar setting such as the pediatric clinic to provide a supportive environment to the patient, or at a ‘bone and metabolic disorder’ clinic, if available to help in seamless transition of care.	

TRAQ, Transition Readiness Assessment Questionnaire; XLH, X-linked hypophosphatemia

Table 10. Asia-Pacific consensus recommendations on the checklist to be passed from the pediatric to adult healthcare provider during transition of care of XLH.

Statement 15		Evidence Quality: Expert Opinion		
The checklist of information that should be passed along with the transfer letter from the pediatric to adult health care provider during the transition of care of patients with XLH from childhood to adulthood may include the following parameters.				
Patient / general information				
Patient information		Details	General healthcare information	Details
Name			Details of comorbid medical conditions (if any)	
Date of Birth	Current age		Current medications	
Date of transfer of care			Current healthcare provider (<i>Name & contact details</i>)	
Gender			Previous healthcare providers (<i>Name & contact details</i>)	
Address and contact number			New healthcare provider (<i>Name & contact details</i>)	
Current insurance details			Details of prior participation in clinical trials	
Informed consent for transition		<input type="checkbox"/> Yes <input type="checkbox"/> No	Additional details (if any)	
Additional details (if any)				
XLH history				
XLH disease history		Details	Documents related to disease history (as attachments)	Details
Age at diagnosis			Renal ultrasound	
Lab results at diagnosis			Radiographs	
Clinical features at diagnosis			Additional imaging results (if any)	
Genetic test results (<i>optional</i>)			Dental images (<i>optional</i>) / records	
Lab results at latest visit			Gait video (<i>optional</i>)	
Hearing evaluation results			Detailed family history and photos (<i>optional</i>)	
Growth chart			Additional documents (if any)	
Functional outcomes (<i>optional</i>)				
Additional details (if any)				

Treatment history (related to XLH)			
Medical treatment	Details of regimen / dose / duration	Surgical procedures	Details
Phosphate salts		Hemi/epiphysiodesis	
Calcitriol		Osteotomy	
Alfacalcidol		Surgery for craniosynostosis	
Burosumab		Additional surgeries (if any)	
Other treatments (if any)			
Complications			
XLH-related complications	Details	Treatment-related complications	Details
Fractures		Nephrocalcinosis/nephrolithiasis	
Pseudofractures		Hyperparathyroidism	
Lower limb deformities		Hypercalciuria / hypercalcemia	
Dental conditions		Renal impairment	
Craniosynostosis		Additional adverse effects (if any)	
Chiari I malformation			
Additional complications (if any)			
Rare disease / XLH advocacy groups / helplines			
Advocacy groups or psychosocial support	<input type="checkbox"/> Yes <input type="checkbox"/> No	Helplines available	<input type="checkbox"/> Yes <input type="checkbox"/> No
If yes, details		If yes, details	
Additional details (if any)			

XLH, X-linked hypophosphatemia

Table 11. Asia-Pacific consensus recommendations for continuing medical education and training in care for XLH.

Statement 16	Evidence Quality: Expert Opinion
<p>The educational or training initiatives that may help pediatric and adult XLH experts to optimize the multidisciplinary management and transition of care of XLH, especially in settings with lack of access to pediatric and/or adult XLH experts include:</p> <ul style="list-style-type: none"> • Development of certified e-learning courses for General Practitioners, General Internists (Internal Medicine Specialists), Endocrinologists, Nephrologists, and Pediatricians, in medical school/medical societies on – <ul style="list-style-type: none"> ○ Diagnosis and management of XLH ○ Transition of care of XLH from childhood to adulthood • Establishing “XLH Centres of Excellence” with XLH experts who can – <ul style="list-style-type: none"> ○ Provide online/tele consultation to HCPs in regions with lack of XLH experts ○ Offer preceptorship programmes to train selected HCPs in the management and care of XLH patients • Organizing focus group meetings, educational symposia or training workshops in collaboration with local endocrine or rare disease societies • Establishing APAC XLH registry in collaboration with key regional/local societies 	

APAC, Asia-Pacific; GRADE, Grading of Recommendations, Assessment, Development and Evaluations; HCP, health care provider; XLH, X-linked hypophosphatemia

Figure 1. Flow diagram for article selection.





Figure 2. Asia-Pacific consensus recommendations on goals of multidisciplinary management of X-linked hypophosphatemia

Statement 4

GRADE Evidence Quality: ⊕⊕⊕⊕ High^a

The goals of multidisciplinary management of X-linked hypophosphatemia should be individualized based on the age and clinical presentation, as shown below.

^aBased on overall evidence supporting the subsequent referral, and monitoring statements, and existing consensus guidelines




JBM4_10744_Figure 2.png

Figure 3: Asia-Pacific consensus recommendations on timelines and goals for optimized transition of care of XLH

Statement 13

Evidence Quality: Expert Opinion

Clinicians treating patients with XLH may consider the following timelines and goals for optimized transition of care from childhood to adulthood.




HCP, health care provider; XLH, X-linked hypophosphatemia

*Depending on the patient's psychosocial and cognitive status; **Subject to availability of validated questionnaires in local languages; ***May vary depending on individual country and healthcare settings (in China, transition to adult care is done at 14 years of age, in Singapore, it is at 18 years and in some settings in Thailand, it is at 15 years).

JBM4_10744_Figure 3.png

Figure 4: Asia-Pacific consensus recommendations on roles and responsibilities to ensure optimized transition of care of XLH



HCP, health care provider; XLH, X-linked hypophosphatemia

JBM4_10744_Figure 4.png

Asia-Pacific Consensus Recommendations on X-Linked Hypophosphatemia: Diagnosis, Multidisciplinary Management, and Transition from Pediatric to Adult Care

15 pediatric and adult endocrinologists (core working group) across Asia-Pacific

+ 23 expert voting group



2 rounds of Delphi Survey

Endorsement by 17 adult & pediatric endocrine/metabolic/bone and mineral research societies*



SCREENING & DIAGNOSIS

Statements 1A and 1B:

Red flags to raise suspicion for renal phosphate wasting conditions in children and adults

Statements 2 and 3:

Clinical, radiological, biochemical, imaging and genetic criteria for diagnosis of XLH in children and adults



MULTIDISCIPLINARY MANAGEMENT/REFERRAL

Statement 4:

Goals for management of XLH

Statements 5A–5E and 6:

Pharmacological treatment of XLH

Statements 7 and 8:

Multidisciplinary referral of patients with XLH

Statements 9–11:

Follow-up monitoring of adults/adolescents/children with XLH

Statement 12:

Telemedicine in XLH care



TRANSITION OF CARE

Statement 13:

Timeline/goals for transition of care

Statement 14A:

Roles and responsibilities of stakeholders

Statement 14B:

Transition questionnaires

Statement 14C:

Transition clinics

Statement 15:

Transfer checklist

Statement 16:

Medical education & training

*Asia Pacific Paediatric Endocrine Society (APPEs), Australia and New Zealand Society for Paediatric Endocrinology and Diabetes (ANZSPED), the Australia and New Zealand Bone and Mineral Society (ANZBMS), Chapter of Endocrinologists, College of Physicians (Singapore), Chinese Society of Osteoporosis and Bone Mineral Research (CSOBMR), Chinese Society of Paediatric Endocrinology and Metabolism (CSPEM), Endocrine and Metabolic Society of Singapore (EMSS), Hong Kong Society of Paediatric Endocrinology and Metabolism (HKSPEM), Japanese Society for Bone and Mineral Research (JSBMR), Japan Endocrine Society (JES), the Japanese Society for Pediatric Endocrinology (JSPE), Korean Society for Bone and Mineral Research (KSBR), the Korean Endocrine Society (KES), Korean Society of Pediatric Endocrinology (KSPE), Malaysian Endocrine and Metabolic Society (MEMS), Taiwan Paediatric Association, and Taiwan Precision Children's Health Association